An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020–2021
TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP, INNOVATION AND ACTION IN PUBLIC HEALTH.

—Public Health Agency of Canada

Également disponible en français sous le titre :
Chapitre sur la grippe du Guide canadien d’immunisation et Déclaration sur l’immunisation sur la vaccination antigrippale pour la saison 2020–2021

To obtain additional information, please contact:

Public Health Agency of Canada
Address Locator 0900C2
Ottawa, ON, K1A 0K9
Tel.: 613-957-2991
Toll free: 1-866-225-0709
Fax: 613-941-5366
TTY: 1-800-465-7735
E-mail: hc.publications-publications.sc@canada.ca

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2020

Publication date: May 2020

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat.: HP37-25E-PDF
ISBN: 2371-5375
Pub.: 200002
PREAMBLE

The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (hereafter referred to as PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.

In addition to burden of disease and vaccine characteristics, PHAC has expanded the mandate of NACI to include the consideration of programmatic factors in developing evidence-based recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels.

The additional factors to be considered by NACI include: economics, ethics, equity, feasibility, and acceptability. Over the coming years NACI will be refining methodological approaches to include these factors. Not all NACI Statements will require in-depth analyses of all programmatic factors. As NACI works towards full implementation of the expanded mandate, select Statements will include varying degrees of programmatic analyses for public health programs.

PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC’s Policy on Conflict of Interest, including yearly declaration of potential conflicts of interest.
# TABLE OF CONTENTS

## I. INTRODUCTION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.1 New or Updated Information for 2020–2021</td>
<td>5</td>
</tr>
<tr>
<td>I.2 Abbreviations for Influenza Vaccines</td>
<td>6</td>
</tr>
<tr>
<td>I.3 Background</td>
<td>6</td>
</tr>
</tbody>
</table>

## II. CANADIAN IMMUNIZATION GUIDE CHAPTER ON INFLUENZA: CLINICAL INFORMATION FOR VACCINE PROVIDERS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>II.1 Key Information</td>
<td>8</td>
</tr>
<tr>
<td>II.2 Epidemiology</td>
<td>15</td>
</tr>
<tr>
<td>II.3 Vaccine Products Authorized for Use in Canada</td>
<td>16</td>
</tr>
<tr>
<td>II.4 Efficacy, Effectiveness, and Immunogenicity</td>
<td>18</td>
</tr>
<tr>
<td>II.5 Choice of Seasonal Influenza Vaccine</td>
<td>18</td>
</tr>
<tr>
<td>II.6 Vaccine Administration</td>
<td>20</td>
</tr>
<tr>
<td>II.7 Vaccine Safety and Adverse Events</td>
<td>23</td>
</tr>
<tr>
<td>II.8 Travellers</td>
<td>25</td>
</tr>
</tbody>
</table>

## III. PARTICULARLY RECOMMENDED VACCINE RECIPIENTS: ADDITIONAL INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>III.1 People at High Risk of Influenza-Related Complications or Hospitalization</td>
<td>27</td>
</tr>
<tr>
<td>III.2 People Capable of Transmitting Influenza to Those at High Risk of Influenza-Related Complications or Hospitalization</td>
<td>29</td>
</tr>
<tr>
<td>III.3 Others</td>
<td>30</td>
</tr>
</tbody>
</table>

## IV. VACCINE PREPARATIONS AUTHORIZED FOR USE IN CANADA: ADDITIONAL INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV.1 Inactivated Influenza Vaccine (IIV)</td>
<td>32</td>
</tr>
<tr>
<td>IV.2 Live Attenuated Influenza Vaccine (LAIV)</td>
<td>38</td>
</tr>
<tr>
<td>IV.3 Schedule</td>
<td>40</td>
</tr>
</tbody>
</table>
IV.4 Simultaneous Administration with Other Vaccines ................................................. 40
IV.5 Additional Vaccine Safety Considerations ................................................................. 41

V. CHOICE OF SEASONAL INFLUENZA VACCINE: ADDITIONAL INFORMATION .......... 43
  V.1 Children .......................................................................................................................... 43
  V.2 Adults .............................................................................................................................. 45

LIST OF ABBREVIATIONS ................................................................................................... 50

ACKNOWLEDGMENTS ........................................................................................................ 52

REFERENCES ....................................................................................................................... 53

APPENDIX A: CHARACTERISTICS OF INFLUENZA VACCINES AVAILABLE FOR USE IN CANADA, 2020–2021 ................................................................. 66
I. INTRODUCTION

This document, the “Advisory Committee Statement: Canadian Immunization Guide Chapter on Influenza and National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2020–2021”, updates NACI’s recommendations regarding the use of seasonal influenza vaccines.

I.1 New or Updated Information for 2020–2021

Updated wording for the recommendation on the vaccination of health care workers and other care providers

NACI recently reassessed the wording for the recommendation on the vaccination of health care workers (HCWs) and other care providers as a group for whom influenza vaccination is particularly recommended. The existing evidence on HCW influenza vaccination and the reduction of morbidity associated with influenza in patients being cared for by a HCW in health care settings was considered in the context of ethics and acceptability. NACI continues to recommend that, in the absence of contraindications, HCWs and other care providers in facilities and community settings should be vaccinated annually against influenza, and recommends the inclusion of this group among the particularly recommended recipients of influenza vaccine. NACI considers the receipt of influenza vaccination to be an essential component of the standard of care for all HCWs and other care providers for their own protection and that of their patients. This group should consider annual influenza vaccination as part of their responsibilities to provide the highest standard of care.

Recommendation on the use of LAIV in HIV-infected individuals

Live attenuated influenza vaccine (LAIV) has been authorized for use in Canada since 2011, and was previously considered contraindicated by NACI in individuals with HIV. Based on a systematic review of the available literature, NACI has concluded that LAIV is immunogenic in children with stable HIV infection on highly active antiretroviral therapy (HAART) and with adequate immune function. NACI also concluded that, while there is insufficient direct evidence to detect uncommon or rare adverse events (AEs) related to the use of LAIV in HIV infected children, LAIV appears to have a similar safety profile to inactivated influenza vaccine (IIV). In addition, some children and their substitute decision makers may prefer that they receive influenza vaccine through an intranasal spray as opposed to an intramuscular (IM) injection, although preferences will vary.

Therefore, NACI recommends that LAIV may be considered as an option for children 2–17 years of age with stable HIV infection on HAART and with adequate immune function (Discretionary NACI Recommendation). LAIV should be considered only in children with HIV who: have been receiving HAART for ≥4 months; have a CD4 count ≥500/µL if 2–5 years of age, or ≥200/µL if 6–17 years of age (measured within 100 days before administration of LAIV); and have HIV plasma ribonucleic acid (RNA) <10,000 copies/mL (measured within 100 days before administration of LAIV).

While IM influenza vaccination still is considered the standard for children living with HIV by NACI and the Canadian Pediatric and Perinatal HIV/AIDS Research Group, LAIV would be reasonable for children meeting the criteria outlined above, if IM vaccination is not accepted by the patient or substitute decision maker. LAIV remains contraindicated in adults with HIV infection due to the
lack of evidence for its immunogenicity and safety, and given that LAIV may be less effective than IIV in adults. Refer to the NACI Statement on the Use of LAIV in HIV-Infected Individuals for additional information supporting this recommendation.

I.2 Abbreviations for Influenza Vaccines

The abbreviations used in this document for the different influenza vaccines authorized in Canada are as follows:

<table>
<thead>
<tr>
<th>Influenza vaccine category</th>
<th>Formulation</th>
<th>Type</th>
<th>Current NACI abbreviationa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactivated influenza vaccine (IIV)</td>
<td>Trivalent (IIV3)</td>
<td>Standard doseb, unadjuvanted, IM administered</td>
<td>IIV3-SD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adjuvantedc, IM administered</td>
<td>IIV3-Adj</td>
</tr>
<tr>
<td></td>
<td></td>
<td>High dosed, unadjuvanted, IM administered</td>
<td>IIV3-HD</td>
</tr>
<tr>
<td>Quadvivalent (IIV4)</td>
<td>Standard doseb, unadjuvanted, IM administered</td>
<td>IIV4-SD</td>
<td></td>
</tr>
<tr>
<td>Live attenuated influenza vaccine (LAIV)</td>
<td>Trivalent (LAIV3)</td>
<td>Unadjuvanted, Nasal spray</td>
<td>LAIV3</td>
</tr>
<tr>
<td></td>
<td>Quadrvivalent (LAIV4)</td>
<td>Unadjuvanted, Nasal spray</td>
<td>LAIV4</td>
</tr>
</tbody>
</table>

**Abbreviations:** IIV: inactivated influenza vaccine; IIV3: trivalent inactivated influenza vaccine; IIV3-Adj: adjuvanted trivalent inactivated influenza vaccine; IIV3-HD: high-dose trivalent inactivated influenza vaccine; IIV3-SD: standard-dose trivalent inactivated influenza vaccine; IIV4: quadrivalent inactivated influenza vaccine; IIV4-SD: standard-dose quadrivalent inactivated influenza vaccine; IM: intramuscular; LAIV: live attenuated influenza vaccine; LAIV3: trivalent live attenuated influenza vaccine; LAIV4: quadrivalent live attenuated influenza vaccine.

a The numeric suffix denotes the number of antigens contained in the vaccine ("3" refers to the trivalent formulation and "4" refers to the quadrivalent formulation). The hyphenated suffix "-SD" is used when referring to IIV products that do not have an adjuvant, contain 15 µg hemagglutinin (HA) per strain and are administered as a 0.5 mL dose by intramuscular injection; "-Adj" refers to an IIV with an adjuvant (e.g., IIV3-Adj for Fluvad® or Fluvad Pediatric®); and "-HD" refers to an IIV that contains higher antigen content than 15 µg HA per strain (e.g., IIV3-HD for Fluzone® High-Dose).

b 15 µg HA per strain.

c 7.5 µg (in 0.25 mL) or 15 µg (in 0.5 mL) HA per strain.
d 60 µg HA per strain.

I.3 Background

The World Health Organization’s (WHO) recommendations on the composition of influenza virus vaccines are typically available in February of each year for the upcoming season in the Northern Hemisphere. The WHO recommends that three influenza strains be included in the trivalent seasonal influenza vaccine: one influenza A(H1N1), one influenza A(H3N2), and one influenza B. Quadrivalent seasonal influenza vaccines should contain the three strains recommended for the trivalent vaccine, as well as an influenza B virus from the lineage that is not included in the trivalent vaccine.
Annual recommendations on the use of influenza vaccine in Canada are developed by the NACI Influenza Working Group (IWG) for consideration by NACI. Recommendations are developed based on a review of a variety of issues, which can include: the burden of influenza illness and the target populations for vaccination; efficacy, effectiveness, immunogenicity, and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization. In addition, PHAC has expanded the mandate of NACI to include the consideration of programmatic factors in developing their recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels. These programmatic factors include economics, ethics, equity, feasibility, and acceptability. Details regarding NACI’s evidence-based process for developing a statement are outlined in Evidence-based Recommendations for Immunization – Methods of the National Advisory Committee on Immunization.

Health care providers in Canada should offer the seasonal influenza vaccine as soon as feasible after it becomes available in the fall, since seasonal influenza activity may start as early as October in the Northern Hemisphere. Decisions regarding the precise timing of vaccination in a given setting or geographic area should be made according to local epidemiologic factors (influenza activity, timing, and intensity), opportune moments for vaccination, as well as programmatic considerations. Further advice regarding the timing of influenza vaccination programs may be obtained through consultation with local public health agencies.

Although vaccination before the onset of the influenza season is strongly preferred, influenza vaccine may still be administered up until the end of the season. Delayed administration may result in lost opportunities to prevent infection from exposures that occur prior to vaccination, and patients should be informed that vaccine administered during an outbreak may not provide optimum protection. Vaccine providers should use every opportunity to administer influenza vaccine to individuals at risk who have not already been vaccinated during the current season, even after influenza activity has been documented in the community.
II. CANADIAN IMMUNIZATION GUIDE CHAPTER ON INFLUENZA: CLINICAL INFORMATION FOR VACCINE PROVIDERS

The Canadian Immunization Guide (CIG) is written primarily for health care providers (frontline clinicians and public health practitioners) but it is also used by policy makers, program planners, and the general public. The CIG has been a trusted, reader-friendly summary of the vaccine statements provided by NACI since 1979.

The information in this section replaces the influenza chapter of the CIG and is adapted for inclusion in the NACI Statement on Seasonal Influenza Vaccine. With a new NACI Statement on Seasonal Influenza Vaccine required each year, readers will have quick access to the information that they require within one document, whether it is the relevant influenza vaccine information written primarily for frontline vaccine providers as is found in this section, or the more detailed technical information that is found in the rest of this statement, commencing in Section III.

II.1 Key Information

The following highlights key information for vaccine providers. Please refer to the remainder of this statement for additional details.

1. What

   - Influenza is a respiratory infection caused primarily by influenza A and B viruses. Seasonal influenza epidemics occur annually in Canada, generally in the late fall and winter months. Influenza occurs globally with an annual attack rate estimated at 5–10% in adults and 20–30% in children\(^1\).

   - Symptoms of influenza typically include the sudden onset of fever, cough, and muscle aches. Other common symptoms include headache, chills, loss of appetite, fatigue, and sore throat. Nausea, vomiting, and diarrhea may also occur, especially in children. Most people will recover within a week to 10 days, but some people are at greater risk of severe complications, such as pneumonia or death. Influenza infection can also worsen certain chronic conditions, such as heart disease\(^2\).

   - Both inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) are authorized for use in Canada; some protect against 3 strains of influenza (i.e., trivalent formulation, IIV3) and some protect against 4 strains of influenza (i.e., quadrivalent formulation, IIV4 or LAIV4).

   - The influenza vaccine is safe and well-tolerated. The influenza vaccine cannot cause influenza illness because inactivated influenza vaccines do not contain live virus and live attenuated influenza vaccines contain weakened viruses.
2. Who

NACI makes the following recommendations for individual-level and public health program-level decision making. Individual-level recommendations are intended for people wishing to protect themselves from influenza or for vaccine providers wishing to advise individual patients about preventing influenza. Program-level recommendations are intended for provinces and territories responsible for making decisions on publicly funded immunization programs. Individual-level and program-level recommendations may differ, as the important factors to consider when recommending a vaccine for a population (e.g., population demographics, economic considerations) may be different than for an individual.

Recommendation for individual-level decision making

- NACI recommends that influenza vaccine should be offered annually to anyone 6 months of age and older who does not have contraindications to the vaccine, with focus on the groups for whom influenza vaccination is particularly recommended (see List 1). These groups include:
  - people at high risk of influenza-related complications or hospitalization;
  - people capable of transmitting influenza to those at high risk;
  - people who provide essential community services; and
  - people in direct contact with poultry infected with avian influenza during culling operations.

Influenza vaccine is less immunogenic in infants less than 6 months of age than in older children and adults and does not confer sufficient protection to make the vaccine useful before 6 months of age\(^{(3)}\). Currently authorized influenza vaccines are not indicated for use in infants less than 6 months of age. For these reasons, NACI recommends that influenza vaccine should not be offered to infants less than 6 months of age. However, infants less than 6 months of age are at high risk of influenza-related illness; therefore the influenza vaccine should be offered to their household contacts, care providers, and pregnant women (see List 1).

Recommendation for public health program-level decision-making

The national goal of the annual influenza immunization programs in Canada is to prevent serious illness caused by influenza and its complications, including death. Programmatic decisions to provide influenza vaccination to target populations as part of publicly funded provincial and territorial programs depend on many factors, such as cost-effectiveness evaluation and other programmatic and operational factors.

- NACI recommends that influenza vaccine should be offered as a priority to the groups for whom influenza vaccination is particularly recommended (see List 1 in the section below).
People for whom influenza vaccination is particularly recommended

List 1: Groups for whom influenza vaccination is particularly recommended

**People at high risk of influenza-related complications or hospitalization**

- All pregnant women;
- Adults and children with the following chronic health conditions:\n  - cardiac or pulmonary disorders (includes bronchopulmonary dysplasia, cystic fibrosis, and asthma);
  - diabetes mellitus and other metabolic diseases;
  - cancer, immune compromising conditions (due to underlying disease, therapy, or both, such as solid organ transplant or hematopoietic stem cell transplant recipients);
  - renal disease;
  - anemia or hemoglobinopathy;
  - neurologic or neurodevelopment conditions (includes neuromuscular, neurovascular, neurodegenerative, neurodevelopmental conditions, and seizure disorders [and, for children, includes febrile seizures and isolated developmental delay], but excludes migraines and psychiatric conditions without neurological conditions);
  - morbid obesity (BMI of 40 and over); and
  - children 6 months to 18 years of age undergoing treatment for long periods with acetylsalicylic acid, because of the potential increase of Reye’s syndrome associated with influenza.
- People of any age who are residents of nursing homes and other chronic care facilities;
- Adults 65 years of age and older;
- All children 6–59 months of age; and
- Indigenous peoples.

**People capable of transmitting influenza to those at high risk**

- Health care and other care providers in facilities and community settings who, through their activities, are capable of transmitting influenza to those at high risk;
- Household contacts, both adults and children, of individuals at high risk, whether or not the individual at high risk has been vaccinated:
  - household contacts of individuals at high risk;
  - household contacts of infants less than 6 months of age, as these infants are at high risk but cannot receive influenza vaccine;
  - members of a household expecting a newborn during the influenza season;
- Those providing regular child care to children 0–59 months of age, whether in or out of the home; and
- Those who provide services within closed or relatively closed settings to people at high risk (e.g., crew on a ship).

**Others**

- People who provide essential community services; and
- People who are in direct contact with poultry infected with avian influenza during culling operations.

---

*a Refer to Immunization of Persons with Chronic Diseases and Immunization of Immunocompromised Persons in Part 3 of the CIG for additional information about vaccination of people with chronic diseases.*
3. How

The benefits and risks of influenza vaccination should be discussed prior to vaccination, including the risks of not being immunized.

Choice of influenza vaccine
A variety of influenza vaccines are authorized for use in Canada, some of which are authorized for use only in specific age groups. Therefore, the choice of influenza vaccine has become more complex. Refer to Section II.5 for recommendations on the choice of influenza vaccine by age group.

Dose and route of administration
The dose and route of administration varies by product (see Section II.6 for details).

- Unadjuvanted IIVs are administered as a 0.5 mL intramuscular (IM) injection for everyone 6 months of age and older;
- MF59-adjuvanted trivalent inactivated influenza vaccine (Fluad®) is administered as a 0.5 mL IM injection for adults 65 years of age and older. A pediatric formulation is also available (Fluad Pediatric®), and is administered as a 0.25 mL IM injection for children 6–23 months of age;
- LAIV (FluMist® Quadrivalent) is administered as 0.2 mL given intranasally (0.1 mL in each nostril) for individuals 2–59 years of age.

Schedule
NACI recommends that:

- Adults and children 9 years of age and older should receive 1 dose of influenza vaccine each year; and
- Children 6 months to less than 9 years of age who have never received the seasonal influenza vaccine in a previous influenza season should be given 2 doses of influenza vaccine in the current season, with a minimum interval of 4 weeks between doses. Children 6 months to less than 9 years of age who have been properly vaccinated with one or more doses of seasonal influenza vaccine in any previous season should receive 1 dose of influenza vaccine per season thereafter.

Contraindications
For all influenza vaccines (IIV and LAIV), NACI recommends that influenza vaccination should not be given to:

- People who have had an anaphylactic reaction to a previous dose of influenza vaccine;
- People who have had an anaphylactic reaction to any of the components of that specific influenza vaccine, with the exception of egg (refer to Section II.7 for more information);
  - If an individual is found to have an anaphylactic reaction to a component in one influenza vaccine, consideration may be given to offering another influenza vaccine that does not contain the implicated component, in consultation with an allergy expert. Individuals who have an allergy to substances that are not
components of the influenza vaccine are not at increased risk of allergy to influenza vaccine.
- Egg allergy is not a contraindication for influenza vaccination, as there is a low risk of AEs associated with the trace amounts of ovalbumin allowed in influenza vaccines manufactured using eggs. Egg-allergic individuals may be vaccinated against influenza using any age-appropriate product, including LAIV, without prior influenza vaccine skin test and with the full dose, irrespective of a past severe reaction to egg, and in any setting where vaccines are routinely administered.
- As with any vaccine product, vaccine providers should be prepared for and have the necessary equipment to respond to a vaccine emergency at all times.

- People who have developed Guillain-Barré Syndrome (GBS) within 6 weeks of a previous influenza vaccination (refer to Section II.7 for more information).
  - The potential risk of GBS recurrence associated with influenza vaccination must be balanced against the risk of GBS associated with influenza infection itself and the benefits of influenza vaccination.

For LAIV, in addition to the above-mentioned contraindications, NACI also recommends that LAIV should not be given to:

- People with immune compromising conditions, with the exception of children with stable HIV infection on HAART and with adequate immune function (see Section IV.2 for more information);
  - Immune compromising conditions may be due to underlying disease, therapy, or both;

- People with severe asthma (defined as currently on oral or high-dose inhaled glucocorticosteroids or active wheezing) or medically attended wheezing in the 7 days prior to the proposed date of vaccination, due to increased risk of wheezing following administration of LAIV;
  - LAIV is not contraindicated for people with a history of stable asthma or recurrent wheeze.

- Children less than 24 months of age, due to increased risk of wheezing following administration of LAIV;

- Children 2–17 years of age currently receiving aspirin or aspirin-containing therapy, because of the association of Reye’s syndrome with aspirin and wild-type influenza infection;
  - In addition, aspirin-containing products in children less than 18 years of age should be delayed for 4 weeks after receipt of LAIV.

- Pregnant women, because it is a live attenuated vaccine and there is a lack of safety data at this time;
  - LAIV is not contraindicated in breastfeeding mothers.

- Receipt of an anti-influenza antiviral drug in the previous 48 hours.
Refer to Contents of Immunizing Agents Available for Use in Canada in Part 1 of the CIG for a list of all vaccines authorized for use in Canada and their contents and to Vaccine Safety in Part 2 of the CIG for information regarding the management of AEs, including anaphylaxis.

**Precautions**

NACI recommends that:

- Influenza vaccination should usually be postponed in people with serious acute illnesses until their symptoms have abated;
  - Vaccination should not be delayed because of minor or moderate acute illness, with or without fever.

- If significant nasal congestion is present that might impede delivery of LAIV to the nasopharyngeal mucosa, IIV can be administered or LAIV can be deferred until resolution of the congestion;

- LAIV recipients should avoid close association with people with severe immune compromising conditions (e.g., bone marrow transplant recipients requiring isolation) for at least 2 weeks following vaccination, because of the theoretical risk for transmitting a vaccine virus and causing infection; and

- LAIV should not be administered until 48 hours after antiviral agents active against influenza (e.g., oseltamivir, zanamivir) are stopped, and those antiviral agents, unless medically indicated, should not be administered until 2 weeks after receipt of LAIV so that the antiviral agents do not kill the replicating vaccine virus.
  - If antiviral agents are administered within this time frame (i.e., from 48 hours pre-vaccination with LAIV to 2 weeks post-vaccination), revaccination should take place at least 48 hours after the antivirals are stopped, or IIV could be given at any time.

- LAIV recipients who are less than 18 years of age should avoid the use of aspirin-containing products for at least 4 weeks after receipt of LAIV.

Refer to Section II.7 for additional information on influenza vaccine-related precautions.

**Simultaneous administration with other vaccines**

NACI recommends that:

- All seasonal influenza vaccines, including LAIV, may be considered for administration at the same time as, or at any time before or after, administration of any other live attenuated or inactivated vaccines (see Section II.6 below for details);
  - It should be noted that no studies have been conducted on the co-administration of recombinant zoster vaccine (RZV) with adjuvanted or high-dose influenza vaccine. No immune response interference or safety concerns have been demonstrated when RZV is administered concomitantly with standard dose, unadjuvanted vaccine[4].

- Different injection sites and separate needles and syringes should be used for concomitant parenteral injections.
4. Why

- Vaccination is the most effective way to prevent influenza and its complications. Vaccinated individuals who are protected from influenza will not pass infection to others. Although most people will recover fully from influenza infection in 7–10 days, influenza can lead to severe complications, including hospitalization and death.

- Annual vaccination is required because the specific strains in the vaccine are reviewed each year by WHO and are often changed to provide a better match against the viruses expected to circulate in that given year, and because the body’s immune response to influenza vaccination is transient and may not persist beyond a year.
II.2 Epidemiology

Disease description

Influenza is a respiratory illness caused by the influenza A and B viruses and can cause mild to severe illness, which can result in hospitalization or death. Certain populations, such as young children, older adults, and those with chronic health conditions, may be at higher risk for serious influenza complications such as viral pneumonia, secondary bacterial pneumonia, and worsening of underlying medical conditions.

Infectious agent

There are two main types of influenza virus that cause seasonal epidemics: A and B. Influenza A viruses are classified into subtypes based on two surface proteins: hemagglutinin (HA) and neuraminidase (NA). Three subtypes of HA (H1, H2, and H3) and two subtypes of NA (N1 and N2) are recognized among influenza A viruses as having caused widespread human disease over the decades. Immunity to the HA and NA proteins reduces the likelihood of infection and together with immunity to the internal viral proteins, lessens the severity of disease if infection occurs.

Influenza B viruses have evolved into two antigenically distinct lineages since the mid-1980s, represented by B/Yamagata/16/88-like and B/Victoria/2/87-like viruses. Viruses from both the B/Yamagata and B/Victoria lineages contribute variably to influenza illness each year.

Over time, antigenic variation (antigenic drift) of strains occurs within an influenza A subtype or a B lineage. The ever-present possibility of antigenic drift, which may occur in one or more influenza virus strains, requires seasonal influenza vaccines to be reformulated annually, with one or more vaccine strains changing in most seasons.

Transmission

Influenza is primarily transmitted by droplets spread through coughing or sneezing and through direct or indirect contact with respiratory secretions. The incubation period of seasonal influenza is usually 2 days but can range from 1–4 days. Adults may be able to spread influenza to others from 1 day before symptom onset to approximately 5 days after symptoms start. Children and people with weakened immune systems may be infectious longer.

Risk factors

The people at greatest risk of influenza-related complications are adults and children with chronic health conditions (see List 1), residents of nursing homes and other chronic care facilities, adults 65 years of age and older, children 0–59 months of age, pregnant women, and Indigenous peoples.

Seasonal and temporal patterns

Influenza activity in Canada is usually low in the late spring and summer, begins to increase over the fall, and peaks in the winter months. Depending on the year, the peak may occur as early as fall or as late as spring. Influenza season in Canada can last from a few weeks to many months, and more than one influenza strain typically circulates each season.
Spectrum of clinical illness

Symptoms typically include the sudden onset of fever, cough, and muscle aches. Other common symptoms include headache, chills, loss of appetite, fatigue, and sore throat. Nausea, vomiting, and diarrhea may also occur, especially in children. Most people will recover within a week or 10 days. However, adults and children with chronic health conditions, adults 65 years of age and older, children 0–59 months of age, residents of long-term care facilities, pregnant women, and Indigenous peoples are at greater risk of more severe complications or worsening of their underlying condition.

Disease incidence

Global
Worldwide, annual epidemics result in approximately one billion cases of influenza, three to five million cases of severe illness, and 290,000 to 650,000 deaths. The global annual attack rate is estimated to be 5–10% in adults and 20–30% in children\(^{(1)}\). For current international influenza activity information, refer to WHO’s FluNet website.

National
Together, influenza and pneumonia are ranked among the top 10 leading causes of death in Canada\(^{(5)}\). The FluWatch program is Canada’s national surveillance system, which monitors the spread of influenza and influenza-like illnesses (ILI) continually throughout the year. Since the 2010–2011 season, an average of 30,000 laboratory-confirmed cases of influenza have been reported to FluWatch each year. Although the burden of influenza can vary from year to year, it is estimated that there are an average of 12,200 hospitalizations related to influenza and approximately 3,500 deaths attributable to influenza annually\(^{(6,7)}\). Current influenza activity information can be found on the FluWatch website.

It should be noted that the incidence of influenza is often underreported since the illness may be confused with other viral illnesses and many people with ILI do not seek medical care or have viral diagnostic testing done.

II.3 Vaccine Products Authorized for Use in Canada

This section describes the influenza vaccine products that are authorized for use in Canada for the 2020–2021 season. All influenza vaccines available in Canada have been authorized by Health Canada. However, not all products authorized for use are necessarily available in the marketplace. The vaccine manufacturers determine whether they will make any or all of their products available in a given market. Provincial and territorial health authorities then determine which of the products available for purchase will be used in their respective publicly funded influenza immunization programs and for which population groups.

The antigenic characteristics of circulating influenza virus strains provide the basis for selecting the strains included in each year’s vaccine. Vaccine selection by the WHO generally occurs more than 6 months prior to the start of the influenza season to allow time for the vaccine manufacturers to produce the required quantity of vaccine. All manufacturers that distribute influenza vaccine products in Canada confirm to Health Canada that the vaccines to be marketed in Canada for the upcoming influenza season contain the WHO’s recommended antigenic strains for the Northern
Hemisphere. Vaccine producers may use antigenically equivalent strains because of their growth properties.

There are two categories of influenza vaccine authorized for use in Canada: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Trivalent (3 strain) vaccines contain one A(H1N1) strain, one A(H3N2) strain, and one influenza B strain from one of the two lineages. Quadrivalent (4 strain) vaccines contain the strains in the trivalent vaccine plus an influenza B strain from the other lineage. All influenza vaccines currently authorized for use in Canada are made from influenza viruses grown in eggs.

A summary of the characteristics of influenza vaccines available in Canada during the 2020–2021 influenza season can be found in Appendix A. For complete prescribing information, readers should consult the product monographs available through Health Canada's Drug Product Database.

**Standard-dose inactivated influenza vaccine (IIV-SD)**

The standard-dose inactivated influenza vaccines (IIV-SDs) currently authorized for use in Canada are a mix of split virus and subunit vaccines. In split virus vaccines, the virus has been disrupted by a detergent. In subunit vaccines, HA and NA have been further purified by removal of other viral components. These vaccines are unadjuvanted, contain 15 µg HA per strain, and are administered as a 0.5 mL dose by IM injection. Refer to Basic Immunology and Vaccinology in Part 1 of the CIG for more information about inactivated vaccines.

Both trivalent (IIV3-SD: Agriflu®, Fluviral®, Influvac®, and Vaxigrip®) and quadrivalent (IIV4-SD: Afluria® Tetra, Flulaval® Tetra, Fluzone® Quadrivalent, and Influvac® Tetra) products are authorized for use in Canada.

**Adjuvanted inactivated influenza vaccine (IIV-Adj)**

The adjuvanted inactivated influenza vaccine (IIV-Adj) currently authorized for use in Canada is a trivalent subunit IIV that contains the adjuvant MF59, which is an oil-in-water emulsion composed of squalene as the oil phase that is stabilized with the surfactants polysorbate 80 and sorbitan trilolate in citrate buffer. IIV-Adj contains 7.5 µg HA per strain administered as a 0.25 mL dose by IM injection for children 6–23 months of age (Fluad Pediatric®) or 15 µg HA per strain administered as a 0.5 mL dose by IM injection for adults 65 years of age and older (Fluad®). Other IIVs do not contain an adjuvant.

**High-dose inactivated influenza vaccine (IIV-HD)**

The high-dose inactivated influenza vaccine (IIV-HD) currently authorized for use in Canada is a trivalent unadjuvanted, split virus IIV that contains 60 µg HA per strain and is administered as a 0.5 mL dose by IM injection (Fluzone® High-Dose).

**Live attenuated influenza vaccine (LAIV)**

LAIV is given as an intranasal spray. The influenza viruses contained in LAIV are attenuated so that they do not cause influenza and are cold-adapted and temperature sensitive, so that they replicate in the nasal mucosa rather than the lower respiratory tract. LAIV contains standardized
quantities of fluorescent focus units (FFU) of live attenuated reassortants and is given as a 0.2 mL dose (0.1 mL in each nostril).

A quadrivalent product (LAIV4; FluMist® Quadrivalent) is authorized for use in Canada for children 2–17 years of age and adults 18–59 years of age. The trivalent formulation (LAIV3) is no longer available in Canada.

II.4 Efficacy, Effectiveness, and Immunogenicity

Efficacy and effectiveness

Influenza vaccine has been shown in randomized controlled clinical trials to be efficacious in providing protection against influenza infection and illness. However, the effectiveness of the vaccine—that is, how it performs in settings that are more reflective of usual health care practice—can vary from season to season and by influenza vaccine strain type and subtype. Influenza vaccine effectiveness (VE) depends on how well the vaccine strains match with circulating influenza viruses, the type and subtype, as well as the health and age of the individual receiving the vaccine. Even when there is a less-than-ideal match or lower effectiveness against one strain, the possibility of lower VE should not preclude vaccination, particularly for people at high risk of influenza-related complications and hospitalization, since vaccinated individuals are still more likely to be protected compared to those who are unvaccinated.

Immunogenicity

Antibody response after vaccination depends on several factors, including the age of the recipient, prior and subsequent exposure to antigens, and the presence of immune compromising conditions. Protective levels of humoral antibodies, which correlate with protection against influenza infection, are generally achieved by 2 weeks after vaccination; however, there may be some protection afforded before that time.

II.5 Choice of Seasonal Influenza Vaccine

The decision to include specific influenza vaccines as part of publicly funded provincial and territorial programs depends on several factors, such as cost-effectiveness evaluation and other programmatic and operational factors, such as implementation strategies. Not all products will be made available in all jurisdictions and availability of some products may be limited; therefore, officials in individual provinces and territories should be consulted regarding the products available in individual jurisdictions.

With the availability of influenza vaccines that are designed to enhance immunogenicity in specific age groups or given through a different route of administration, the choice of product has become more complex.
Choice of influenza vaccine by age group

Recommendations for individual-level decision making
- NACI recommends that influenza vaccine should be offered annually to anyone 6 months of age and older who does not have contraindications to the vaccine. Table 2 provides age group-specific recommendations for the age-appropriate influenza vaccine types authorized for use in Canada.

Recommendations for public health program-level decision making
- NACI recommends that any of the age-appropriate influenza vaccine types available for use may be considered for people without contraindications to the vaccine. Table 2 provides age group-specific recommendations for the age-appropriate influenza vaccine types authorized in Canada.

Table 2: Recommendations on choice of influenza vaccine type for individual- and public health program-level decision making by age group

<table>
<thead>
<tr>
<th>Recipient by age group</th>
<th>Vaccine types authorized for use</th>
<th>Recommendations on choice of influenza vaccine</th>
</tr>
</thead>
</table>
| 6–23 months            | • IIV3-SD<br>• IIV3-Adj<br>• IIV4-SD | • Quadrivalent influenza vaccine should be used in infants without contraindications, given the burden of influenza B disease in this age group and the potential for lineage mismatch between the predominant circulating strain of influenza B and the strain in a trivalent vaccine.  
  - If a quadrivalent vaccine is not available, any of the available trivalent vaccines should be used. |
| 2–17 years a           | • IIV3-SD<br>• IIV4-SD<br>• LAIV4 | • Either IIV4-SD or LAIV4 should be used in children without contraindications, including those with non-immune compromising chronic health conditions, given the burden of influenza B disease in this age group and the potential for lineage mismatch between the predominant circulating strain of influenza B and the strain in a trivalent vaccine.  
  - If IIV4-SD or LAIV4 is not available, IIV3-SD should be used.  
  - IIV4-SD should be used for children for whom LAIV is contraindicated, such as in children with:  
    - severe asthma;  
    - medically attended wheezing in the 7 days prior to vaccination;  
    - current receipt of aspirin or aspirin-containing therapy; and  
    - immune compromising conditions, with the exception of stable HIV infection, if the child is currently being treated with highly active antiretroviral therapy (HAART) and has adequate immune function.  
  - LAIV4 may be given to children with:  
    - stable, non-severe asthma;  
    - cystic fibrosis who are not being treated with immunosuppressive drugs (e.g., prolonged systemic corticosteroids); and |
## II.6 Vaccine Administration

### Dose, route of administration, and schedule

With the variety of influenza vaccines available for use in Canada, it is important for vaccine providers to note the specific differences in age indication, route of administration, dosage, and schedule for the products that they will be using (see Table 3). Key relevant details and differences between vaccine products are also highlighted in Appendix A.
For influenza vaccines given by the IM route, the anterolateral thigh muscle is the recommended site in infants 6–12 months of age. The anterolateral thigh or the deltoid muscle can be used for toddlers and older children. The deltoid muscle of the arm is the preferred injection site in adolescents and adults. For more information on vaccine administration, please refer to Vaccine Administration Practices in Part 1 of the CIG.

### Table 3: Recommended dose and route of administration, by age, for influenza vaccine types authorized for the 2020–2021 influenza season

<table>
<thead>
<tr>
<th>Age group</th>
<th>IIV3-SD(^a) or IIV4-SD(^b) (IM)</th>
<th>IIV3-Adj(^c) (IM)</th>
<th>IIV3-HD(^d) (IM)</th>
<th>LAIV4(^e) (intranasal)</th>
<th>Number of doses required</th>
</tr>
</thead>
<tbody>
<tr>
<td>6–23 months</td>
<td>0.5 mL(^f)</td>
<td>0.25 mL</td>
<td>-</td>
<td>-</td>
<td>1 or 2(^g)</td>
</tr>
<tr>
<td>2–8 years</td>
<td>0.5 mL</td>
<td>-</td>
<td>-</td>
<td>0.2 mL (0.1 mL per nostril)</td>
<td>1 or 2(^g)</td>
</tr>
<tr>
<td>9–17 years</td>
<td>0.5 mL</td>
<td>-</td>
<td>-</td>
<td>0.2 mL (0.1 mL per nostril)</td>
<td>1</td>
</tr>
<tr>
<td>18–59 years</td>
<td>0.5 mL</td>
<td>-</td>
<td>-</td>
<td>0.2 mL (0.1 mL per nostril)</td>
<td>1</td>
</tr>
<tr>
<td>60–64 years</td>
<td>0.5 mL</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>65 years and older</td>
<td>0.5 mL</td>
<td>0.5 mL</td>
<td>0.5 mL</td>
<td>-</td>
<td>1</td>
</tr>
</tbody>
</table>

Abbreviations: IIV3-Adj: adjuvanted trivalent inactivated influenza vaccine; IIV3-HD: high-dose trivalent inactivated influenza vaccine; IIV3-SD: standard-dose trivalent inactivated influenza vaccine; IIV4-SD: standard-dose quadrivalent inactivated influenza vaccine; IM: intramuscular; LAIV4: quadrivalent live attenuated influenza vaccine.

\(^a\) Agriflu\(^®\) (6 months and older), Fluviral\(^®\) (6 months and older), Influvac\(^®\) (3 years and older), Vaxigrip\(^®\) (6 months and older). Influvac\(^®\) and Vaxigrip\(^®\) are authorized, but not currently available for sale in Canada.

\(^b\) Afluria\(^®\) Tetra (5 years and older), Flulaval\(^®\) Tetra (6 months and older), Fluzone\(^®\) Quadrivalent (6 months and older), Influvac\(^®\) Tetra (18 years and older). Influvac\(^®\) Tetra is authorized for use in Canada in adults 18 years and older; however, NACI has not specifically reviewed this product.

\(^c\) Fluarix Pediatric\(^®\) (6–23 months) or Fluad\(^®\) (65 years and older)

\(^d\) Fluzone\(^®\) High-Dose (65 years and older)

\(^e\) FluMist\(^®\) Quadrivalent (2–59 years)

\(^f\) Evidence suggests moderate improvement in antibody response in infants, without an increase in reactogenicity, with the use of full vaccine doses (0.5 mL) for unadjuvanted inactivated influenza vaccines\(^8,9\). This moderate improvement in antibody response without an increase in reactogenicity is the basis for the full dose recommendation for unadjuvanted inactivated vaccine for all ages. For more information, refer to Statement on Seasonal Influenza Vaccine for 2011–2012.

\(^g\) Children 6 months to less than 9 years of age receiving seasonal influenza vaccine for the first time in their life should be given 2 doses of influenza vaccine, with a minimum interval of 4 weeks between doses. Children 6 months to less than 9 years of age who have been properly vaccinated with one or more doses of seasonal influenza vaccine in the past should receive 1 dose of influenza vaccine per season thereafter.
Booster doses and revaccination

Booster doses are not required within the same influenza season. However, children 6 months to less than 9 years of age who have not previously received the seasonal influenza vaccine require 2 doses of influenza vaccine, with a minimum of 4 weeks between doses (see Table 3). Only one dose of influenza vaccine per season is recommended for everyone else. Two doses of seasonal influenza vaccine in older adults do not appear to improve the immune response to the vaccine compared to one dose\(^{(11)}\).

Serological testing

Serologic testing is not necessary before or after receiving seasonal influenza vaccine.

Storage requirements

Influenza vaccine should be stored at +2°C to +8°C and should not be frozen. Refer to the individual product monographs for further details. Refer to Storage and Handling of Immunizing Agents in Part 1 of the CIG for additional information.

Simultaneous administration with other vaccines

In theory, the administration of two live vaccines sequentially within less than 4 weeks could reduce the efficacy of the second vaccine. Studies have been done showing no interference when administering LAIV3 concomitantly with: measles, mumps, rubella (MMR); measles, mumps, rubella, varicella (MMRV); or oral polio live vaccines\(^{(10, 12, 13)}\). No studies have been done to assess the possibility of interference between LAIV and other live vaccines, or on LAIV given before or after other live vaccines. Additional information regarding simultaneous administration with other vaccines can be found in Section IV.4 of this statement.

Given the lack of data for immune interference, and based on expert opinion, NACI recommends that LAIV can be given together with or at any time before or after the administration of any other live attenuated or inactivated vaccine. However, some vaccine providers may continue to choose to give LAIV and other live vaccines separated by at least 4 weeks, based on the theoretical possibility of immune interference, although NACI does not believe that this precaution is necessary for LAIV. The use of an inactivated influenza vaccine would avoid this theoretical concern. Note that the timing rules related to two parenteral live vaccines (e.g., MMR and varicella vaccines) still apply. For more information regarding vaccination administration timing rules, please refer to Timing of Vaccine Administration in Part 1 of the CIG.

When more than one injection is given at a single clinic visit, it is preferable to administer them in different limbs. If it is not possible to do so, injections given in one limb should be separated by a distance of at least 2.5 cm (1 inch). A separate needle and syringe should be used for each injection.

The target groups for influenza and pneumococcal polysaccharide vaccines overlap considerably. Vaccine providers should take the opportunity to vaccinate eligible people against pneumococcal disease when influenza vaccine is given.
Simultaneous administration with recombinant zoster vaccine
RZV is a recombinant adjuvanted subunit herpes zoster vaccine (Shingrix®, GlaxoSmithKline) that is authorized for use in Canada in adults 50 years of age and older; therefore, the target age group for herpes zoster vaccine and influenza vaccine overlap. RZV has been shown to be safe and effective when given concomitantly with unadjuvanted, standard dose influenza vaccines. However, no studies have been conducted that have assessed the co-administration of RZV with adjuvanted or high dose influenza vaccine. It should be noted that the RZV and IIV-adj currently authorized for use in Canada contain the adjuvants AS01B and MF59 respectively. How these adjuvants may interact when RZV and IIV-adj are administered concomitantly is not known.

II.7 Vaccine Safety and Adverse Events

Post-marketing surveillance of influenza vaccines in Canada has shown that seasonal influenza vaccines have a safe and stable profile. In addition to routine surveillance, every year during the seasonal influenza vaccination campaigns, PHAC and the Federal/Provincial/Territorial Vaccine Vigilance Working Group (VVG) of the Canadian Immunization Committee conduct weekly expedited surveillance of AEFIs for current influenza vaccines in order to identify vaccine safety signals in a timely manner. Refer to the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) web page for more information on post-marketing surveillance and AEFIs in Canada.

All influenza vaccines currently authorized for use in Canada are considered safe for use in people with latex allergies. The multi-dose vial formulations of inactivated influenza vaccine that are authorized for use in Canada contain minute quantities of thimerosal, which is used as a preservative to keep the product sterile. Large cohort studies of administrative health databases have found no association between childhood vaccination with thimerosal-containing vaccines and neurodevelopmental outcomes, including autistic-spectrum disorders. All single dose formulations of IIV and LAIV are thimerosal-free. Refer to Vaccine Safety in Part 2 of the CIG for additional information.

Common adverse events

With IM administered influenza vaccines, injection site reactions are common but are generally classified as mild and transient. IIV3-Adj tends to produce more extensive injection site reactions than unadjuvanted IIV3, but these reactions are also generally mild and resolve spontaneously within a few days. IIV3-HD tends to induce higher rates of systemic reactions post-injection compared to IIV3-SD, but most of these reactions are mild and short-lived. The most common AEs experienced by recipients of LAIV3 are nasal congestion and runny nose, which are also reported for LAIV4. Refer to the relevant subsections of Section IV for additional information.

Less common and serious or severe adverse events

Serious adverse events (SAEs) are rare following influenza vaccination, and in most cases, data are insufficient to determine a causal association. Allergic responses to influenza vaccine are a rare consequence of hypersensitivity to some vaccine components. Refer to Section IV.5 below for additional information.
Other reported adverse events and conditions

Guillain-Barré syndrome
Studies suggest that the absolute risk of Guillain-Barré syndrome (GBS) in the period following seasonal and A(H1N1)pdm09 influenza vaccination is about one excess case per million vaccinations\(^{18,19}\), and that the risk of GBS associated with influenza illness is larger (about 17 cases per million influenza-coded health care encounters, which are a proxy for influenza illness) than that associated with influenza vaccination\(^{19}\).

Although the evidence considering influenza vaccination and GBS is inadequate to accept or reject a causal relation between GBS in adults and seasonal influenza vaccination, avoiding subsequent influenza vaccination of individuals known to have had GBS without other known etiology within 6 weeks of a previous influenza vaccination appears prudent at this time. However, the potential risk of GBS recurrence associated with influenza vaccination must be balanced against the risk of GBS associated with influenza infection itself and the benefits of influenza vaccination.

Oculorespiratory syndrome
Oculorespiratory syndrome (ORS), which is defined as the presence of bilateral red eyes and one or more associated respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness, or sore throat) that starts within 24 hours of vaccination, with or without facial oedema, was identified during the 2000–2001 influenza season\(^{20}\). Since then, there have been far fewer cases per year reported to CAEFISS\(^{21}\). ORS is not considered to be an allergic response. People who have a recurrence of ORS upon vaccination do not necessarily experience further episodes with future vaccinations.

Individuals who have experienced ORS without lower respiratory tract symptoms may be safely revaccinated with influenza vaccine. Individuals who experienced ORS with lower respiratory tract symptoms should have an expert review. Health care providers who are unsure whether an individual previously experienced ORS versus an immunoglobulin E (IgE) mediated hypersensitivity immune response should seek advice. Data on clinically significant AEs do not support the preference of one vaccine product over another when revaccinating those who have previously experienced ORS.

Allergic reactions to previous vaccine doses
Expert review of the benefits and risks of vaccination should be sought for those who have previously experienced severe lower respiratory symptoms (wheeze, chest tightness, difficulty breathing) within 24 hours of influenza vaccination, an apparent significant allergic reaction to the vaccine, or any other symptoms that could indicate a significant allergic reaction (e.g., throat constriction, difficulty swallowing) that raise concern regarding the safety of revaccination. This advice may be obtained from experts in infectious disease, allergy, and immunology, or public health.

In view of the considerable morbidity and mortality associated with influenza, a diagnosis of influenza vaccine allergy should not be made without confirmation, which may involve consultation with an allergy or immunology expert.
Drug interactions

Although influenza vaccine can inhibit the clearance of warfarin and theophylline, clinical studies have not shown any adverse effects attributable to these drugs in people receiving influenza vaccine. Statins have effects on the immune system in addition to their therapeutic cholesterol-lowering actions. Two published studies have found that adults who are regular statin users (at least 65 years of age\textsuperscript{22} in one study and 45 years and older in the other\textsuperscript{23}) had an apparent decreased response to influenza vaccination as measured by reduced geometric mean titres (GMT)\textsuperscript{22} or reduced VE against medically attended acute respiratory illness\textsuperscript{23}. Statins are widely used in the same adult populations who are also at-risk for influenza-related complications and hospitalizations. Therefore, if these preliminary findings are confirmed in future studies, concomitant statin use in adult populations could have implications for influenza VE and how this use is assessed in the measurement of VE. NACI will continue to monitor the literature related to this issue.

Guidance on reporting adverse events following immunization

To ensure the ongoing safety of influenza vaccines in Canada, reporting of AEFIs by vaccine providers and other clinicians is critical, and in most jurisdictions, reporting is mandatory under the law.

An AEFI is any untoward medical occurrence that follows vaccination and that does not necessarily have a causal relationship with the usage of a vaccine. The AE may be any unfavourable or unintended sign, abnormal laboratory finding, symptom, or disease. In general, any AE felt to be temporally related to vaccination and for which there is no other clear cause at the time of reporting should be reported. Of particular interest are those AEFIs which are considered serious or unexpected. A serious AEFI is an AE that is life threatening or results in death, requires hospitalization or prolongation of an existing hospitalization, results in residual disability or causes congenital malformation\textsuperscript{24}. An unexpected AEFI is an event that is not listed in the approved product monograph but may be due to the vaccination, or one whose nature, severity, specificity, or outcome is not consistent with the term or description used in the product monograph\textsuperscript{24}. Vaccine providers are asked to report AEFIs through local public health officials and to check for specific AEFI reporting requirements in their province or territory. If there is any doubt as to whether or not an event should be reported, a conservative approach should be taken and the event should be reported.

For influenza vaccines, the following AEFIs are of particular interest:

- ORS; and
- GBS within 6 weeks following vaccination.

Refer to Reporting Adverse Events Following Immunization (AEFI) in Canada for additional information about AEFI reporting and to Vaccine Safety in Part 2 of the CIG for general vaccine safety information.

II.8 Travellers

Influenza occurs year-round in the tropics. In temperate northern and southern countries, influenza activity generally peaks during the winter season (November to March in the Northern Hemisphere and April to October in the Southern Hemisphere).
NACI recommends that influenza vaccine should be offered annually to anyone 6 months of age and older, including travellers, who does not have contraindications to the vaccine, with focus on the groups for whom influenza vaccination is particularly recommended (see List 1). Vaccines prepared specifically for use in the Southern Hemisphere are not available in Canada, and the extent to which recommended vaccine components for the Southern Hemisphere may overlap with those in available Canadian formulations will vary. A decision for or against revaccination (i.e., boosting) of travellers to the Southern Hemisphere between April and October, if they had already been vaccinated in the preceding fall or winter with the Northern Hemisphere’s vaccine, depends on individual risk assessment, the similarity or difference between the Northern and Southern Hemisphere vaccines, the similarity or difference between the Northern Hemisphere vaccine strains and currently circulating strains in the Southern Hemisphere, and the availability of a reliable and safe vaccine at the traveller’s destination. Refer to Immunization of Travellers in Part 3 of the CIG for additional general information.

This concludes the summary of relevant influenza vaccine information typically found in the Canadian Immunization Guide. Additional technical information related to seasonal influenza vaccine can be found in the remainder of this statement.
III. PARTICULARLY RECOMMENDED VACCINE RECIPIENTS: ADDITIONAL INFORMATION

The groups for whom influenza vaccination is particularly recommended are presented in List 1 of Section II. Additional information regarding these particularly recommended recipients is provided below.

III.1 People at High Risk of Influenza-Related Complications or Hospitalization

All pregnant women

NACI recommends the inclusion of all pregnant women, at any stage of pregnancy, among the particularly recommended recipients of IIV, due to the risk of influenza-associated morbidity in pregnant women\(^{(25-29)}\), evidence of adverse neonatal outcomes associated with maternal respiratory hospitalization or influenza during pregnancy\(^{(30-33)}\), evidence that vaccination of pregnant women protects their newborns from influenza and influenza-related hospitalization\(^{(34-37)}\), and evidence that infants born during influenza season to vaccinated women are less likely to be premature, small for gestational age, and of low birth weight than if born to women that had not received an influenza vaccine\(^{(38-41)}\). The risk of influenza-related hospitalization increases with length of gestation (i.e., it is higher in the third trimester than in the second).

The safety of IIV during pregnancy has been reviewed\(^{(42)}\). Active studies of influenza vaccination during pregnancy have not shown evidence of harm to the mother or fetus associated with influenza vaccination\(^{(43)}\). Although the cumulative sample size of active studies of influenza vaccination in pregnant women is relatively small, particularly in the first trimester, passive surveillance has not raised any safety concerns despite widespread use of IIV during pregnancy over several decades\(^{(27,28,42,44)}\). Surveillance following the use of both adjuvanted and unadjuvanted 2009 pandemic influenza A(H1N1) vaccines in more than 100,000 pregnant women in Canada and more than 488,000 pregnant women in Europe\(^{(45)}\) has not revealed any safety concerns.

Refer to the Statement on Seasonal Influenza Vaccine for 2011–2012 and the Statement on Seasonal Influenza Vaccine for 2012–2013 for further details on influenza vaccination during pregnancy.

Adults and children with chronic health conditions

A number of chronic health conditions, as noted in List 1, are associated with increased risk of influenza-related complications, and influenza can lead to exacerbation of the chronic disease. Influenza vaccination can induce protective antibody levels in a substantial proportion of adults and children with immune compromising conditions, including transplant recipients, those with proliferative diseases of the hematopoietic and lymphatic systems, and HIV-infected people. Vaccine effectiveness may be lower in people with immune compromising conditions than in healthy adults.
Neurologic or neurodevelopment conditions

Neurologic or neurodevelopment conditions (NNCs) include neuromuscular, neurovascular, neurodegenerative, neurodevelopment conditions, and seizure disorders (and, for children, include febrile seizures and isolated developmental delay), but exclude migraines and psychiatric conditions without neurological conditions. Based on reviews of evidence and expert opinion, NACI includes adults and children with NNCs among the groups for whom influenza vaccination is particularly recommended. Refer to the NACI Statement on Seasonal Influenza Vaccine for 2018–2019 for a summary of the rationale supporting this decision and the Literature Review on Individuals with Neurologic or Neurodevelopment Conditions and Risk of Serious Influenza-Related Complications for additional details of the evidence reviews.

People of any age who are residents of nursing homes and other chronic care facilities

Residents of nursing homes and other chronic care facilities often have one or more chronic health conditions and live in institutional environments that may facilitate the spread of influenza.

Adults 65 years of age and older

Hospitalization attributable to influenza in this age group is estimated at 125–228 per 100,000 healthy people\(^{(46)}\), and influenza-attributed mortality rates increase with increased age\(^{(47)}\).

All children 6–59 months of age

On the basis of existing data, NACI recommends the inclusion of all children 6–59 months of age among the particularly recommended recipients of influenza vaccine.


Indigenous peoples

Based on the body of evidence indicating a higher rate of influenza-associated hospitalization and death among Indigenous peoples, NACI recommends the inclusion of this population among the particularly recommended recipients of influenza vaccine.

It has been proposed that the increased risk of severe influenza outcomes in the Indigenous populations is a consequence of many factors, including high prevalence of chronic health conditions (e.g., diabetes, chronic lung disease, end-stage kidney disease, cardiovascular disease\(^{(48)}\), obesity, delayed access to health care, and increased susceptibility to disease because of poor housing and overcrowding\(^{(49-51)}\). Refer to the Statement on Seasonal Influenza Vaccine for 2011–2012 for further details.
III.2 People Capable of Transmitting Influenza to Those at High Risk of Influenza-Related Complications or Hospitalization

People who are potentially capable of transmitting influenza to those at high risk should receive annual vaccination, regardless of whether the high-risk individual has been vaccinated. Vaccination of HCWs decreases their own risk of illness and as well as the risk of death and other serious outcomes among the individuals for whom they provide care. Vaccination of HCWs and residents of nursing homes is associated with decreased risk of ILI outbreaks.

People who are more likely to transmit influenza to those at high risk of influenza-related complications or hospitalization include:

- HCWs and other care providers in facilities and community settings who, through their activities, are capable of transmitting influenza to those at high risk; and
- Contacts, both adults and children, of individuals at high risk, whether or not the individual at high risk has been vaccinated.

Health care workers and other care providers in facilities and community settings

**Vaccination of health care workers and other care providers**

For the purposes of this statement, HCWs and other care providers in facilities and community settings refers to HCWs, regular visitors, emergency response workers, and others who have contact with residents of continuing care or long-term care facilities or residences, those who provide home care for people at high risk, and students of related health care services. HCWs include any person, paid or unpaid, who provides services, works, volunteers, or trains in a hospital, clinic, or other health care facility.

Transmission of influenza to patients at high risk of influenza-associated complications results in significant morbidity and mortality. Four cluster randomized controlled trials (RCTs) conducted in geriatric long-term care settings have demonstrated that vaccination of HCWs is associated with substantial decreases in influenza-like illness and all-cause mortality in the residents. In addition, due to their occupation and close contact with people at high-risk of influenza-related complications, HCWs are themselves at increased risk of infection.

As previously stated, adults and children with chronic health conditions, adults 65 years of age and older, and children 0–59 months of age are at greater risk of more severe complications from influenza or worsening of their underlying condition. Given the potential for HCWs and other care providers to transmit influenza to individuals at high risk and knowing that vaccination is the most effective way to prevent influenza, NACI recommends that, in the absence of contraindications, HCWs and other care providers in facilities and community settings should be vaccinated against influenza annually. NACI considers the receipt of influenza vaccination to be an essential component of the standard of care for all HCWs and other care providers for their own protection and that of their patients. This group should consider annual influenza vaccination as part of their responsibilities to provide the highest standard of care.

Although current influenza vaccine coverage for HCWs is higher than in the general public, it remains below the national goal of 80% coverage for HCWs in Canada. Comprehensive vaccination programs should be adopted that address HCWs’ acceptance of the vaccine and...
facilitate the process of vaccinating HCWs to improve uptake of the influenza vaccine beyond the current level. HCW influenza vaccination programs that have successfully increased vaccine coverage of HCWs have included a combination of education, increased awareness, accessible on-site vaccination delivery options for all HCWs, visible support from senior staff and other leaders, and regular review and improvement of vaccination strategies\(^\text{63-68}\).

**Outbreak management in health care facilities**

As noted in PHAC’s Guidance: Infection Prevention and Control Measures for Healthcare Workers in Acute Care and Long-term Care Settings for seasonal influenza, all health care organizations should have a written plan for managing an influenza outbreak in their facilities. Inherent in such plans should be policies and programs to optimize HCW’s influenza vaccination\(^\text{69}\). As part of outbreak management, the above-mentioned PHAC guidance suggests consideration of chemoprophylaxis for all unvaccinated HCWs, unless contraindications exist. Refer to the Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada) website for guidelines regarding the use of antiviral medications for prophylaxis.

**Contacts of individuals at high risk of influenza complications**

Vaccination is recommended for contacts, both adults and children, of individuals at high risk of influenza-related complications or hospitalization (see List 1), whether or not the individual at high risk has been vaccinated. These contacts include: household contacts and care providers of individuals at high risk, household contacts and care providers of infants less than 6 months of age (as these infants are at high risk of complications from influenza but cannot receive influenza vaccine), members of a household expecting a newborn during the influenza season, household contacts and care providers (whether in or out of the home) of children 6–59 months of age, and providers of services within closed or relatively closed settings with people at high risk of influenza-related complications (e.g., crew on a ship).

**III.3 Others**

**People who provide essential community services**

Vaccination for these individuals should be encouraged to minimize the disruption of services and routine activities during annual influenza epidemics. People who provide essential community services, including healthy working adults, should consider annual influenza vaccination, as this intervention has been shown to decrease work absenteeism due to respiratory and related illnesses\(^\text{52,53,70-72}\).

**People in direct contact with poultry infected with avian influenza during culling operations**

**Poultry workers**

Although seasonal influenza vaccination will not prevent avian influenza infection, some countries\(^\text{73}\) and provinces have recommended influenza vaccination on a yearly basis for poultry workers, based on the rationale that preventing infection with human influenza strains may reduce the theoretical potential for human-avian reassortment of genes, should such workers become co-infected with human and avian influenza viruses\(^\text{74}\).
NACI recommends seasonal influenza vaccination for people in direct contact with poultry infected with avian influenza during culling operations, as these individuals may be at increased risk of avian influenza infection because of exposure during the culling operation (75-78). Refer to the Statement on Seasonal Influenza Vaccine for 2013–2014 for further information informing this recommendation.

Direct contact may be defined as sufficient contact with infected poultry to allow transmission of an avian virus to the exposed person. The relevant individuals include those performing the cull, as well as others who may be directly exposed to the avian virus, such as supervising veterinarians and inspectors. It is recommended that biosecurity measures such as personal protective equipment and antivirals be used. Refer to Human Health Issues Related to Avian Influenza in Canada for PHAC recommendations on the management of domestic avian influenza outbreaks.

**Swine workers**

NACI has concluded that there is insufficient evidence at this time to recommend routine influenza vaccination specifically for swine workers; however, NACI recommends that influenza vaccination should be offered to anyone 6 months of age and older who does not have contraindications to the vaccine.

Refer to the Statement on Seasonal Influenza Vaccine for 2013–2014 for further information informing this recommendation.
IV. VACCINE PREPARATIONS AUTHORIZED FOR USE IN CANADA: ADDITIONAL INFORMATION

The following sections describe information on the efficacy and effectiveness, immunogenicity, and safety of influenza vaccines that are authorized for use in Canada by type: IIV and LAIV. Refer to Appendix A for a summary of the characteristics of specific influenza vaccine products available in Canada for the 2020–2021 season.

NACI acknowledges that evidence related to influenza vaccine performance, particularly with respect to vaccine efficacy and effectiveness, is constantly evolving with advances in research methodology and accumulation of data over many influenza seasons. Therefore, the evidence summarized in this section may not include the latest studies. However, in accordance with usual practice, NACI continues to closely monitor the emerging evidence on the efficacy and effectiveness, immunogenicity, and safety of influenza vaccines to update and to make recommendations when warranted.

IV.1 Inactivated Influenza Vaccine (IIV)

IIVs contain standardized amounts of the HA protein from representative seed strains of the two human influenza A subtypes (H3N2 and H1N1) and either one (for trivalent vaccines) or both (for quadrivalent vaccines) of the two influenza B lineages (Yamagata or Victoria). IIVs currently authorized for use in Canada are a mix of split virus and subunit vaccines, both consisting of disrupted virus particles. Split virus vaccines contain whole inactivated viruses split with detergent, ether, or both, while subunit vaccines are made of purified HA and NA. The amount of NA in the vaccines is not standardized. HA-based serum antibody produced to one influenza A subtype is anticipated to provide little or no protection against strains belonging to the other subtype. The potential for trivalent vaccine to stimulate antibody protection across B lineages requires further evaluation and may be dependent upon factors such as age and prior antigenic experience with the two B lineages\(^{79-84}\).

Because of potential changes in the circulating influenza virus from year to year and waning immunity in vaccine recipients, annual influenza vaccination is recommended. Although NACI is aware of some recent studies that suggest that vaccine induced protection may be greater in individuals who have no recent vaccine history, optimal protection against influenza, season after season, is best achieved through annual influenza vaccination\(^{85,86}\). NACI will continue to monitor this issue.

**Immunological considerations related to children**

Young children have a high burden of illness and their vaccine-induced immune response is not as robust as older children. However, some studies suggest moderate improvement in antibody response in young children, without an increase in reactogenicity, with the use of a full vaccine dose (0.5 mL) for IIV-SDs\(^{8,9,87}\). On the basis of this moderate improvement in antibody response without an increase in reactogenicity, NACI recommends the use of a 0.5 mL dose for all recipients of IIV-SDs, including young children.

**Immunological considerations related to older adults and those with immune compromising conditions**

Although the initial antibody response in older adults may be lower to some influenza vaccine components when compared to those in other age groups, a literature review identified no
Evidence for a subsequent antibody decline that was any more rapid in older adults than in younger age groups\(^{(88)}\).

Influenza vaccination can induce protective antibody levels in a substantial proportion of adults and children with immune compromising conditions, including transplant recipients, those with proliferative diseases of the hematopoietic and lymphatic systems, and HIV-infected patients\(^{(89-92)}\).

Most studies have shown that administration of a second dose of influenza vaccine in the same season to older adults or other individuals who may have an altered immune response does not result in a clinically significant antibody boost\(^{(11, 93-95)}\).

**Standard-dose trivalent inactivated influenza vaccine (IIV3-SD)**

Vaccines currently authorized for use:

- Agriflu\(^{®}\) (Seqirus)
- Fluviral\(^{®}\) (GlaxoSmithKline)
- *Influvac\(^{®}\) (BGP Pharma ULC, operating as Mylan)
- *Vaxigrip\(^{®}\) (Sanofi Pasteur Ltd.)

*Vaccine is not currently available in Canada.

**Efficacy and effectiveness**

The NACI Literature Review on Influenza Vaccination in Healthy 5–18 Year Olds found that VE of IIV3-SD against laboratory-confirmed influenza was variable but was most frequently between 65–85\(^{\%}\)\(^{(96-114)}\). In the NACI literature review on Influenza Vaccine Effectiveness, Immunogenicity, and Safety in Healthy Adults 19–64 Years Old, efficacy against laboratory-confirmed influenza for IIV3-SD in healthy adults 18–64 years of age ranged widely from as low as 15\(^{\%}\) to as high as 75\(^{\%}\), with the majority of studies estimating efficacy at 50–60\(^{\%}\). Refer to the Statement on Seasonal Influenza Vaccine for 2018–2019 for a more detailed summary of efficacy and effectiveness evidence for IIV3-SD in healthy children 5–18 years of age and healthy adults 19–64 years of age.

In older adults, VE of IIV3-SD is about half of that in healthy adults and varies depending on the outcomes measured and the study population\(^{(115, 116)}\). Systematic reviews have demonstrated that influenza vaccine decreases the incidence of pneumonia, hospital admissions, and deaths in older adults\(^{(115)}\) and reduces exacerbations in people with chronic obstructive pulmonary disease\(^{(117)}\). The NACI Literature Review on the Comparative Effectiveness and Immunogenicity of Subunit and Split Virus Inactivated Influenza Vaccines in Adults 65 Years of Age and Older found no statistically significant differences in VE of subunit IIV3-SD compared with split virus IIV3-SD in adults 65 years of age and older against infection with any influenza virus strain, or against infection with influenza A(H1N1), A(H3N2), or B virus specifically.

In observational studies, influenza vaccination has been shown to reduce the number of physician visits, hospitalizations, and deaths in adults 18–64 years of age with high-risk medical conditions\(^{(118)}\), hospitalizations for cardiac disease and stroke in adults 65 years of age and older\(^{(119)}\), and hospitalization and deaths in adults 18 years of age and older with diabetes mellitus\(^{(120)}\) during influenza epidemics. Observational studies that use non-specific clinical outcomes or that do not take into account differences in functional status or health-related behaviours should be interpreted with caution\(^{(121-125)}\).
Immunogenicity
Both humoral and cell-mediated immune responses are thought to play a role in immunity to influenza. While humoral immunity is thought to play a primary role in protection against infection, cell-mediated immunity, notably cytotoxic T lymphocyte responses to internal viral components, is increasingly invoked as important in protecting against severe outcomes of influenza, particularly those associated with subtype HA variations (shift and drift)\(^{(126)}\). The IM administration of IIV3-SD results in the production of circulating immunoglobulin G (IgG) antibodies to the viral HA and NA proteins, as well as a more limited cytotoxic T lymphocyte response.

Safety
Studies evaluating the safety of IIV3-SDs in healthy children have found a good safety profile with no SAEs of note\(^{(127)}\). The most common solicited local reactions are pain and redness at the injection site, while the most common solicited systemic reactions are irritability, malaise, and headache. Mild injection site reactions, primarily soreness at the vaccination site, have been found to occur in 7% or less of healthy children who are less than 3 years of age\(^{(128-130)}\). Post-vaccination fever may be observed in 12% or less of vaccinated children 1–5 years of age\(^{(101,130)}\).

For adults, IIV3-SDs have been demonstrated to have a good safety profile with acceptable reactogenicity\(^{(127)}\). Common local reactions at injection site include redness, swelling, pain, and induration. These reactions last 2–3 days and rarely interfere with normal activities. Common systemic reactions include headache, malaise, myalgia, fatigue, arthralgia, and fever.

Adjuvanted trivalent inactivated influenza vaccine (IIV3-Adj)

Vaccines currently authorized for use:

- Fluad\textsuperscript{®} (Seqirus)
- Fluad Pediatric\textsuperscript{®} (Seqirus)

1. Fluad (adults 65 years of age and older)

Efficacy and effectiveness
There is fair evidence that the MF59-adjuvanted Fluad (IIV3-Adj) may be effective at reducing the risk of hospitalization for influenza and influenza complications in older adults compared to unvaccinated individuals. However, there is insufficient evidence that IIV3-Adj is more effective at reducing the risk of hospitalization for influenza and influenza complications in older adults compared to those who received unadjuvanted subunit IIV3-SD. Refer to the NACI Literature Review Update on the Efficacy and Effectiveness of High-Dose and MF59-Adjuvanted Trivalent Inactivated Influenza Vaccines in Adults 65 Years of Age and Older for more information on the efficacy and effectiveness of IIV3-Adj in adults 65 years of age and older.

Immunogenicity
The mechanism of action of MF59 is not fully determined and has primarily been studied using in vitro and mouse models. From these studies, it appears that MF59 may act differently from aluminum-based adjuvants. These studies show that MF59 acts in the muscle fibres to create a local immune-stimulatory environment at the injection site\(^{(131)}\). MF59 allows for an increased influx of phagocytes (e.g., macrophages, monocytes) to the site of injection. The recruited phagocytes are further stimulated by MF59, thereby increasing the production of chemokines to attract more innate immune cells and inducing differentiation of monocytes into dendritic cells\(^{(132,133)}\). MF59 further facilitates the internalization of antigen by these dendritic cells\(^{(132,134)}\). The overall higher number of cells available locally increases the likelihood of interaction between an antigen
presenting cell and the antigen, leading to more efficient transport of antigen to the lymph nodes, with resulting improved T cell priming\(^{(132)}\).

There is evidence from RCTs that IIV3-Adj elicits non-inferior immune responses compared to the unadjuvanted subunit and split virus IIV3-SDs; however, superiority of IIV3-Adj to these vaccines by pre-defined criteria has not been consistently demonstrated. Refer to the Statement on Seasonal Influenza Vaccine for 2018–2019 for more information on the immunogenicity of IIV3-Adj in adults 65 years of age and older.

Safety
IIV3-Adj produces injection site reactions (pain, erythema, and induration) significantly more frequently than IIV3-SD, but they are classified as mild and transient. Systemic reactions (myalgia, headache, fatigue, and malaise) are comparable or more frequent with IIV3-Adj compared to IIV3-SD and are rated as mild to moderate and transient. SAEs were uncommon and were comparable to IIV3-SD. Refer to the Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad\(^{®}\)): Supplemental Statement of Seasonal Influenza Vaccine for 2011–2012 for additional information on the safety of IIV3-Adj in adults 65 years of age and older.

2. **Fluad Pediatric (children 6–23 months of age)**

Efficacy and effectiveness
A pre-licensure efficacy trial in children 6–71 months of age found a higher relative efficacy for IIV-Adj than the unadjuvanted IIV3-SD\(^{(135)}\). However, the findings of this study should be interpreted with caution. The comparator unadjuvanted IIV3 used in this trial was shown, in an unrelated study, to induce a lower immune response compared to another unadjuvanted IIV3-SD. There were concerns raised by a European Medicines Agency inspection about the quality of diagnostic laboratory testing and validity of ascertainment of influenza cases. The study administered 0.25 mL doses of the comparator unadjuvanted IIV3-SD for children less than 36 months of age, which is lower than the dose of 0.5 mL of unadjuvanted IIV3-SD or IIV4-SD that is recommended for this age group in Canada. Refer to the NACI Literature Review on Pediatric Fluad\(^{®}\) Influenza Vaccine Use in Children 6–72 Months of Age for more information on the efficacy and effectiveness of IIV3-Adj in children.

Immunogenicity
In children, there is limited but consistent evidence that IIV3-Adj is more immunogenic than IIV3-SD against both influenza A and B\(^{(135-140)}\). In particular, a single dose of IIV3-Adj is more immunogenic than a single dose of IIV3-SD, and has been shown in one study to produce greater GMTs than 2 doses of IIV3-SD against influenza A\(^{(140)}\). However, similar to IIV3-SD, IIV3-Adj generally induced a weaker hemagglutination-inhibition antibody response against B strains compared to A strains and therefore 2 doses of IIV3-Adj are still necessary to achieve a satisfactory immune response against influenza B.

Almost all of the pre-licensure pediatric studies used vaccine formulations of 0.25 mL in children 6–35 months of age, both for IIV3-Adj and the comparator unadjuvanted influenza vaccine (NACI recommends 0.5 mL dosage of IIV3-SD or IIV4-SD for all age groups). There is limited immunogenicity evidence comparing IIV3-Adj at 0.25 mL dose to IIV3-SD or IIV4-SD at 0.5 mL dose in the 6–23 month age group. Refer to the NACI Literature Review on Pediatric Fluad\(^{®}\) Influenza Vaccine Use in Children 6–72 Months of Age for more information on the immunogenicity of IIV3-Adj in children.
Safety
The safety data in children are consistent with what is known about IIV3-Adj’s safety profile in adults. In pediatric trials, IIV3-Adj was more reactogenic than IIV3-SD, with recipients experiencing 10–15% more solicited local and systemic reactions. However, most reactions were mild and resolved quickly. A dose-ranging study of MF59-adjuvanted and unadjuvanted IIV3 and IIV4 did not find an increased risk of AEs associated with increased MF59 dose, antigen dose, or the addition of a second B strain; however, the reactogenicity of 15 µg formulations were slightly higher for both adjuvanted and unadjuvanted vaccines compared to the corresponding 7.5 µg formulations.¹³⁸

There are currently no data on the effects of long-term or repeated administration of adjuvanted influenza vaccines in children. The most significant experience with an adjuvanted influenza vaccine in children was the AS03-adjuvanted A(H1N1) pandemic vaccine that has been associated with an increased risk of narcolepsy. A study comparing two AS03-adjuvanted A(H1N1) vaccine products (Pandemrix and Arepanrix) has suggested that the underlying immune mediated mechanism associated with the increased narcolepsy risk may not be initiated by the adjuvant, but by the A(H1N1) nucleoprotein viral antigen, given that the study found significant antigenic differences between the two A(H1N1) pandemic vaccines.¹⁴¹ However, the pandemic vaccine was a single strain adjuvanted vaccine administered only during one season, and it is unknown what effects a multi-strain adjuvanted vaccine or an adjuvanted vaccine administered for more than one season may have in young children.

Refer to the NACI Literature Review on Pediatric Fluad® Influenza Vaccine Use in Children 6-72 Months of Age for additional information on the safety of IIV3-Adj in children.

High-dose trivalent inactivated influenza vaccine (IIV3-HD)

Vaccine currently authorized for use:

- Fluzone® High-Dose (Sanofi Pasteur)

Efficacy and effectiveness
There is good evidence that Fluzone High-Dose (IIV3-HD) provides better protection compared with IIV3-SD in adults 65 years of age and older. A few studies found that IIV3-HD may provide greater benefit in adults 75 years of age and older compared to adults 65–74 years of age;¹⁴² however, additional studies are needed to validate this finding. There remain no efficacy or effectiveness studies that compare IIV3-HD with IIV3-Adj or IIV4-SD specifically.

Refer to the NACI Literature Review Update on the Efficacy and Effectiveness of High-Dose and MF59-Adjuvanted Trivalent Inactivated Influenza Vaccines in Adults 65 Years of Age and Older for more information on the efficacy and effectiveness of IIV3-HD in adults 65 years of age and older.

Immunogenicity
Five studies compared the rates of seroconversion for study participants receiving IIV3-HD and IIV3-SD among those 65 years of age and older.¹⁴⁵-¹⁵⁰ Rates of seroconversion were found to be about 19% higher (ranging from 8–39% higher) for those receiving the higher dose vaccine across all three vaccine strains. Similarly, rates of seroconversion were higher for those receiving the high- compared to standard-dose vaccines for participants 75 years of age and older and for a cohort of participants with underlying cardiopulmonary disease.
Eight studies reported higher rates of seroprotection for older adults receiving IIV3-HD compared to those vaccinated with IIV3-SD\(^{(145-152)}\). Seroprotection was significantly higher for all 3 strains in the vaccine in three of five studies assessing significance. There were different results in the remaining studies. In the study by Couch et al., seroprotection was higher only against A(H1N1), possibly attributed to the fact that 78% of participants were vaccinated against the same influenza strains within 6 months prior to the study\(^{(146)}\). In Nace et al., seroprotection was higher against A(H3N2) and B but not A(H1N1); the lack of higher seroprotection against A(H1N1) may be attributed to strain circulation during the study that made it difficult to assess seroprotection against this subtype\(^{(150)}\).

Geometric mean titre ratios (GMTR) of participants’ responses to high- versus standard-dose influenza vaccines were reported in several studies and were calculated for those that provided group-specific, post-vaccination titres for each of the vaccines\(^{(145,149,151,152)}\). Seroresponse to the B strains in the vaccines was about 1.5 times greater (1.3–1.7) in the IIV3-HD recipients than the IIV3-SD recipients. The GMTR of the A strains was about 1.8 times higher for those receiving IIV3-HD compared to IIV3-SD, ranging from 1.6–2.3.

**Safety**

IIV3-HD has been observed to produce a higher rate of some systemic and local reactions than IIV3-SD. Studies have reported higher rates of malaise, myalgia, and moderate to severe fever. Most systemic reactions were mild and resolved within 3 days. SAEs were rare and similar in frequency between standard-dose and high-dose vaccines.

Refer to NACI’s A Review of the Literature of High Dose Seasonal Influenza Vaccine for Adults 65 Years and Older for details.

**Standard-dose quadrivalent inactivated influenza vaccine (IIV4-SD)**

Vaccines currently authorized for use:

- Afluria® Tetra (Seqirus)
- Flulaval® Tetra (GlaxoSmithKline)
- Fluzone® Quadrivalent (Sanofi Pasteur)
- Influvac® Tetra (BGP Pharma ULC, operating as Mylan)

**Efficacy and effectiveness**

In the NACI Literature Review on Quadrivalent Influenza Vaccines, only one study was identified that measured IIV4-SD efficacy. In that study, efficacy was estimated at 59% in children 3–8 years of age, in comparison to children who received hepatitis A vaccine\(^{(153)}\). No literature was found in this review on efficacy or effectiveness directly comparing trivalent and quadrivalent formulations.

**Immunogenicity**

In the same review of the literature noted above, NACI reviewed the immunogenicity data for IIV4-SD produced by manufacturers who supplied influenza vaccine in Canada at the time of the literature review: AstraZeneca, GlaxoSmithKline, and Sanofi Pasteur. The results of phase II and III trials that compared trivalent formulations to quadrivalent formulations generally showed non-inferiority of the quadrivalent products for the A(H3N2), A(H1N1), and B strain contained in the trivalent formulations. As expected, these studies showed that the immune response to the B strain that was not in the trivalent formulation was better in subjects who received the quadrivalent
vaccine, which contained the additional B strain. These findings were consistent across age groups. Refer to the Literature Review on Quadrivalent Influenza Vaccines for additional details.

In the phase III trials, recipients of the trivalent formulations showed, to a lesser degree, some immune response to the B strain not contained in the trivalent formulation. In one study of adults, both the trivalent and quadrivalent vaccines met all the European Medicines Agency Committee for Medicinal Products for Human Use and the United States Food and Drug Administration criteria for evaluation of influenza vaccine immunogenicity, including those for the B strain not in the trivalent vaccine.

In all other studies, the trivalent vaccine failed at least one of the criteria for seroprotection or seroconversion for the missing B strain. It has been hypothesized that there is some level of cross-reactivity between B strains. The degree of cross protection against infection with one lineage provided by immunization against the other lineage is uncertain\(^\text{154}\).

**Safety**

As IIV4-SD has higher antigenic content than IIV3-SD, increased reactogenicity may be a concern for the quadrivalent vaccine. However, pre-licensure clinical trials (refer to Literature Review on Quadrivalent Influenza Vaccines) and post-marketing surveillance showed that IIV4-SD had a similar safety profile to IIV3-SD\(^\text{155}\).

**IV.2 Live Attenuated Influenza Vaccine (LAIV)**

LAIV contains standardized quantities of FFU of live attenuated influenza virus reassortants. The virus strains in LAIV are cold-adapted and temperature sensitive, so they replicate in the nasal mucosa rather than the lower respiratory tract, and they are attenuated, so they do not produce ILI. There have been no reported or documented cases, and no theoretical or scientific basis to suggest transmission of vaccine virus would occur to the individual administering LAIV. As a live replicating whole virus formulation administered intranasally, it elicits mucosal immunity, which may more closely mimic natural infection.

Vaccine currently authorized for use:

- FluMist\(^\text{\textregistered}\) Quadrivalent (AstraZeneca)

**Efficacy and effectiveness**

After careful review of the available Canadian and international LAIV VE data over many influenza seasons, NACI concluded that the current evidence is consistent with LAIV providing comparable protection against influenza to that afforded by IIV and does not support a recommendation for the preferential use of LAIV in children 2–17 years of age.

Observational studies from the United States found low effectiveness of LAIV against circulating post-2009 pandemic A(H1N1), or A(H1N1)pdm09, in 2013–2014 and 2015–2016; however, reduced LAIV effectiveness was not observed in Canada or any other countries that have investigated the issue. Manufacturer investigation identified potential reduced replicative fitness of the A(H1N1)pdm09-like LAIV viruses in the nasal mucosa from the two affected A(H1N1)-dominant seasons compared to pre-2009 pandemic influenza A(H1N1) LAIV viruses as contributing to the poor LAIV effectiveness against circulating A(H1N1)\(^\text{156}\). This finding led to the manufacturer replacing the A(H1N1)pdm09 component of LAIV with new strains, with the
A/Slovenia/2903/2015 being the strain that has been used since the 2017–2018 season. In adults, studies have found IIV-SD to be similarly or more efficacious or effective compared with LAIV.

Refer to the Statement on Seasonal Influenza Vaccine for 2018–2019 for detailed information supporting this recommendation.

**Immunogenicity**

LAIV, which is administered by the intranasal route, is thought to result in an immune response that mimics that induced by natural infection with wild-type viruses, with the development of both mucosal and systemic immunity. Local mucosal antibodies protect the upper respiratory tract and may be more important for protection than serum antibody.

Studies have demonstrated that the presence of a hemagglutination-inhibition antibody response after the administration of LAIV3 is predictive of protection. However, efficacy studies have shown protection in the absence of a significant antibody response as well. In these studies, LAIV3 has generally been shown to be equally, if not more, immunogenic compared to IIV3-SD for all 3 strains in children, whereas IIV3-SD was typically more immunogenic in adults than LAIV3. Greater rates of seroconversion to LAIV3 occurred in baseline seronegative individuals compared to baseline seropositive individuals in both pediatric and adult populations, because pre-existing immunity may interfere with response to a live vaccine. Refer to the NACI Recommendations on the Use of Live, Attenuated Influenza Vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011–2012 for further details regarding the immunogenicity of LAIV3.

LAIV4 has shown non-inferiority based on immunogenicity compared to LAIV3 in both children and adults. The immune response to the B strain found only in the quadrivalent formulation was better in children who received the quadrivalent vaccine.

**Safety**

The most common AEs experienced by recipients of LAIV3 are nasal congestion and runny nose, which are also reported for LAIV4. In a large efficacy trial, rates of wheezing were statistically higher among children 6–23 months of age for LAIV3 compared to IIV3-SD. This finding is expected to be the same for recipients of LAIV4; however, pre-licensure clinical studies for LAIV4 were conducted only in adults and children 2 years of age and older.

Studies on LAIV3 have shown that vaccine virus can be recovered by nasal swab in children and adults following vaccination (i.e., “shedding”). The frequency of shedding decreases with increasing age and time since vaccination. Shedding is generally below the levels needed to transmit infection, although in rare instances, shed vaccine viruses can be transmitted from vaccine recipients to unvaccinated people. Refer to the NACI Recommendations on the Use of Live, Attenuated Influenza Vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011–2012 for more information on LAIV and viral shedding.

**Considerations related to individuals with HIV infection**

Following a review of the literature regarding the use of LAIV in HIV-infected individuals, NACI concluded that LAIV is immunogenic in children with stable HIV infection on HAART and with adequate immune function. In addition, NACI concluded that LAIV appears to have a similar safety profile as IIV in children on HAART and with stable HIV infection with regard to frequency and severity of AEs. As expected, injection site reactions were seen only with IIV and nasal symptoms were more common with LAIV. However, the evidence base is too small to effectively detect uncommon, rare, and very rare AEs related to the use of LAIV in this population. In addition, nasal spray may be preferable to IM injection for some individuals who are averse to...
receiving the vaccine by injection. Therefore, NACI recommends that LAIV may be considered as an option for children 2–17 years of age with stable HIV infection on HAART and with adequate immune function. LAIV should be considered only in children with HIV who meet the following criteria:

- Receiving HAART for ≥4 months;
- CD4 count ≥500/µL if 2–5 years of age, or ≥200/µL if 6–17 years of age (measured within 100 days before administration of LAIV); and
- HIV plasma RNA <10,000 copies/mL (measured within 100 days before administration of LAIV).

IM influenza vaccination is still considered the standard for children living with HIV by NACI and the Canadian Pediatric and Perinatal HIV/AIDS Research Group, particularly for those without HIV viral load suppression (i.e. plasma HIV RNA >40 copies/mL). However, if IM vaccination is not accepted by the patient or substitute decision maker, LAIV would be a reasonable option for children meeting the criteria listed above.

Refer to the NACI Statement on the Use of LAIV in HIV-Infected Individuals for more information on the use of LAIV in this population.

**IV.3 Schedule**

The first time that children 6 months to less than 9 years of age receive seasonal influenza vaccination, a two-dose schedule is required to achieve protection. Several studies have looked at whether these two initial doses need to be given in the same season or separated. Englund et al. reported similar immunogenicity in children 6–23 months of age whether 2 doses were given in the same or separate seasons when there was no change, or only minor vaccine strain change, in vaccine formulation between seasons. However, seroprotection rates to the B component were considerably reduced in the subsequent season when there was a major B lineage change, suggesting that the major change in B virus lineage reduced the priming benefit of previous vaccination. Issues related to effective prime-boost when there is a major change in influenza B lineage across sequential seasons require further evaluation. Because children 6–23 months of age are less likely to have had prior priming exposure to an influenza virus, special effort is warranted to ensure that a two-dose schedule is followed for previously unvaccinated children in this age group.

**IV.4 Simultaneous Administration with Other Vaccines**

In general, NACI recommends that two live parenteral vaccines be administered either on the same day or at least 4 weeks apart. This recommendation is based largely on a single study from 1965 that demonstrated immune interference between smallpox vaccine and measles vaccine administered 9–15 days apart. Subsequent studies have revealed conflicting results on immune interference between live vaccines. No studies were found on potential immune interference between LAIV and other live attenuated vaccines (oral or parenteral) administered within 4 weeks. A few studies on concomitant administration of LAIV3 with MMR, varicella, and oral polio vaccines did not find evidence of clinically significant immune interference. One study reported a statistically significant but not clinically meaningful decrease in seroresponse rates to rubella antigen when administered concomitantly with LAIV.
In theory, the administration of two live vaccines sequentially within less than 4 weeks could reduce the efficacy of the second vaccine. Possible immune mechanisms include: the inhibitory and immunomodulatory effects of systemic and locally produced cytokines on B- and T-cell response and viral replication; immunosuppression induced by certain viruses (such as measles); and direct viral interference as a result of competition for a common niche. Mucosal vaccines may have less impact on a parenteral vaccine and vice versa. The immune response with a mucosal vaccine may be compartmentalized to the mucosa while that to a parenteral vaccine is systemic. It is likely that there is some interaction between the systemic and mucosal compartments; however, the extent to which this interaction occurs is not known.

Given the lack of data for immune interference, and based on expert opinion, NACI recommends that LAIV can be given together with or at any time before or after the administration of any other live attenuated or inactivated vaccine. However, some vaccine providers may continue to choose to give LAIV and other live vaccines separated by at least 4 weeks, based on the theoretical possibility of immune interference, although NACI does not believe that this precaution is necessary for LAIV. The use of an inactivated influenza vaccine would avoid this theoretical concern.

IV.5 Additional Vaccine Safety Considerations

Influenza vaccine is safe and well tolerated. Contraindications, precautions, and common AEs are described in Section II. Additional information regarding egg-allergic individuals and GBS is provided below.

Egg-allergic individuals

After careful review of clinical and post-licensure safety data, NACI has concluded that egg-allergic individuals may be vaccinated against influenza using any appropriate product, including LAIV, without prior influenza vaccine skin test and with the full dose, irrespective of a past severe reaction to egg and without any particular consideration, including vaccination setting. The amount of trace ovalbumin allowed in influenza vaccines that are authorized for use in Canada is associated with a low risk of AE. The observation period post-vaccination is as recommended in Vaccine Safety in Part 2 of the CIG. As with all vaccine administration, vaccine providers should be prepared with the necessary equipment, knowledge, and skills to respond to a vaccine emergency at all times.

Refer to the Statement on Seasonal Influenza Vaccine for 2018–2019 for safety data supporting this recommendation for IIV and LAIV.

Guillain-Barré syndrome

In a review of studies conducted between 1976 and 2005, the United States Institute of Medicine concluded that the 1976 “swine flu” vaccine was associated with an elevated risk of GBS. However, evidence was inadequate to accept or to reject a causal relation between GBS in adults and seasonal influenza vaccination\(^\text{171}\).

The attributable risk of GBS in the period following seasonal and monovalent 2009 pandemic influenza vaccination is about one excess case per million vaccinations\(^\text{18,19}\). In a self-controlled study that explored the risk of GBS after seasonal influenza vaccination and after influenza healthcare encounters (a proxy for influenza illness), the attributable risks were 1.03 GBS admissions
per million vaccinations compared with 17.2 GBS admissions per million influenza-coded health care encounters\(^{19}\). This finding shows that both influenza vaccination and influenza illness are associated with small attributable risks of GBS, but the risk of GBS associated with influenza illness is notably higher than with influenza vaccination. The self-controlled study also found that the risk of GBS after vaccination was highest during weeks 2–4, whereas for influenza illness, the risk was greatest within the first week after a health care encounter and decreased thereafter, but remained significantly elevated for up to 4 weeks. The risk of GBS associated with influenza vaccination must be balanced against the risk of GBS associated with influenza infection itself and all the other benefits of influenza vaccination\(^{172-175}\).
V. CHOICE OF SEASONAL INFLUENZA VACCINE: ADDITIONAL INFORMATION

With the recent availability of a number of new influenza vaccines, some of which are designed to enhance immunogenicity in specific age groups, the choice of product is now more complex. Section II.5 summarizes NACI’s recommendations on the choice of currently authorized influenza vaccines. This section provides more details for these recommendations.

V.1 Children

Burden of disease in children

The proportion of disease burden due to influenza B infection is higher in children compared to other age groups. Canadian surveillance data from 2001–2002 to 2012–2013 has shown that influenza B strains accounted for 17% of laboratory-confirmed tests for influenza. Children less than 24 months of age comprise approximately 2% of the Canadian population\(^{(176)}\).

Using case-based laboratory data from 2001–2012 (excluding 2009), children 0–23 months of age averaged 10.8% of reported influenza B cases (range: 8.3–13.7%). With respect to severe outcomes (e.g., hospitalization, intensive care unit admission, and death), influenza B was confirmed in 15.5–58.3% (median: 38.4%) of pediatric influenza-associated hospitalizations (children 16 years of age and younger) reported by the Canadian Immunization Monitoring Program Active (IMPACT) surveillance network between 2004–2005 and 2012–2013 (excluding the 2009–2010 pandemic season)\(^{(177)}\).

The IMPACT study also found that the proportion of deaths attributable to influenza was significantly greater for children admitted to hospital with influenza B (1.1%) than for those admitted with influenza A (0.4%). The proportion of hospitalizations due to influenza B relative to all influenza hospitalizations has been generally similar to the proportion of influenza B detections relative to all influenza infections in the general population during the same time period. Additional information can be found in the Statement on Seasonal Influenza Vaccine for 2014–2015.

In the NACI Literature Review on Quadrivalent Influenza Vaccines, a review of B lineage antigens included in the Canadian influenza vaccines and the circulating strains each season indicates a match in five of the 12 seasons from 2001–2002 through to 2012–2013, a moderate match (about 50% from each lineage) in 1 season, and a mismatch in remaining 6 influenza seasons (i.e., 70% or more of the characterized B strains were of the opposite lineage to the antigen in that season’s vaccine).

Children 6–23 months of age

Three types of influenza vaccine are authorized for use in children 6–23 months of age: IIV3-SD, IIV3-Adj, and IIV4-SD.

Given the burden of influenza B disease in children and the potential for lineage mismatch between the predominant circulating strain of influenza B and the strain in a trivalent vaccine, NACI recommends that a quadrivalent influenza vaccine should be used. If a quadrivalent vaccine is not available, any of the available age-appropriate trivalent vaccines should be used.
There is insufficient evidence to make comparative recommendations on the use of IIV3-Adj over IIV3-SD.

**Children 2–17 years of age**

Three types of influenza vaccine are authorized for use in children 2–17 years of age: IIV3-SD, IIV4-SD, and LAIV4.

Given the burden of influenza B disease in children and the potential for lineage mismatch between the predominant circulating strain of influenza B and the strain in a trivalent vaccine, NACI recommends that a quadrivalent vaccine should be used. If a quadrivalent vaccine is not available, an age-appropriate trivalent vaccine should be used.

The current evidence does not support a recommendation for the preferential use of LAIV in children and adolescents 2–17 years of age. Refer to the NACI Statement on Seasonal Influenza Vaccine for 2018–2019 for information supporting this recommendation.

**Children 2–17 years of age with chronic health conditions**

NACI recommends that any age-appropriate influenza vaccine (IIV or LAIV) may be considered for children 2–17 years of age with chronic health conditions, with the exception of those with severe asthma (as defined as currently on oral or high-dose inhaled glucocorticosteroids), those with medically attended wheezing in the 7 days prior to vaccination, and those with immune compromising conditions, excluding those with stable HIV infection on HAART and with adequate immune function. Children for whom LAIV is contraindicated should receive IIV. If IIV is used, NACI recommends that a quadrivalent vaccine should be used. If a quadrivalent vaccine is not available, an age-appropriate trivalent vaccine should be used.

NACI recommends that LAIV may be given to children with stable, non-severe asthma, children with cystic fibrosis who are not treated with immunosuppressive drugs, such as prolonged systemic corticosteroids, and children with stable HIV infection on HAART and with adequate immune function.

Refer to the NACI Recommendations on the Use of Live, Attenuated Influenza Vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011–2012 for additional information supporting these recommendations.

**Summary of vaccine characteristics for decision making**

IIV (IIV3-SD and IIV4-SD) and LAIV (LAIV4) are authorized for use in Canada for children 2–17 years of age. The comparison of the vaccine characteristics of IIV and LAIV, in Table 4 below, may be considered in making a decision on the preferred vaccine option(s) for use by an individual or a public health program.
Table 4: Vaccine characteristics of live attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine (IIV) in children 2–17 years of age

<table>
<thead>
<tr>
<th>Considerationsa</th>
<th>LAIVb compared with IIVc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy and effectiveness</td>
<td>There was early evidence of superior efficacy of LAIV3 compared with IIV3-SD in children less than 6 years of age from randomized controlled trials, with weaker evidence of superior efficacy in older children. However, later post-marketing and surveillance studies across multiple influenza seasons found comparable protection against influenza for LAIV and IIV, with findings of reduced effectiveness for LAIV against A(H1N1) in some studies.</td>
</tr>
<tr>
<td></td>
<td>Like IIV4-SD, LAIV4 is expected to provide additional protection against the influenza B strain not contained in IIV3-SD.</td>
</tr>
<tr>
<td>Immunogenicity</td>
<td>LAIV3 has been shown to be as immunogenic as IIV3-SD, depending on age, with LAIV4 being non-inferior to LAIV3.</td>
</tr>
<tr>
<td>Safety</td>
<td>Rhinitis (runny nose) and nasal congestion are more common with LAIV. Clinical studies and post-marketing studies showed a similar safety profile to IIV.</td>
</tr>
<tr>
<td>Contraindications</td>
<td>There are vaccine contraindications specific to LAIV. LAIV is contraindicated for children with severe asthma, medically attended wheezing in the 7 days prior to vaccination, and immune compromising conditions (with the exception of children with stable HIV infection on HAART and with adequate immune function), as well as those currently receiving aspirin or aspirin-containing therapy. LAIV is also contraindicated for pregnant adolescents.</td>
</tr>
<tr>
<td>Acceptability</td>
<td>Delivery of LAIV as a nasal spray may be preferable for children who are averse to receiving the vaccine by needle injection.</td>
</tr>
</tbody>
</table>

Abbreviations: HAART: highly active antiretroviral therapy; IIV: inactivated influenza vaccine; IIV3-SD: standard-dose trivalent inactivated influenza vaccine; IIV4-SD: standard-dose quadrivalent inactivated influenza vaccine; LAIV: live attenuated influenza vaccine; LAIV3: trivalent live attenuated influenza vaccine; LAIV4: quadrivalent live attenuated influenza vaccine.

a NACI has not assessed the comparative cost-effectiveness of authorized influenza vaccine types for children 2–17 years of age.
b The trivalent formulation of LAIV (LAIV3) received a Notice of Compliance from Health Canada in June 2010 and was first used in publicly funded immunization programs in Canada for the 2012–2013 influenza season. The quadrivalent formulation (LAIV4) was approved for use in Canada for the 2014–2015 season and has been in use since that time. LAIV3 is no longer available in Canada.
c Both trivalent and quadrivalent IIV-SD (IIV3-SD and IIV4-SD) are authorized for use in Canada for the 2020–2021 influenza season.

V.2 Adults

Burden of disease in adults

A study focusing on estimates of deaths associated with influenza in the United States has established that the average annual rate of influenza-associated deaths for adults aged 65 years of age and older was 17.0 deaths per 100,000 (range: 2.4–36.7)\(^{(178)}\). The study also states that of deaths coded as being influenza- or pneumonia-related, persons 65 years of age and older
accounted for 87.9% of the overall estimated annual average number of influenza-associated deaths. When influenza-related deaths among adults 65 years of age and older were estimated using underlying respiratory and circulatory causes, these estimates increased to 66.1 deaths per 100,000 (range: 8.0–121.1) and 89.4%, respectively. This study described a wide variation in the estimated number of deaths from season to season, which was closely related to the particular influenza virus types and subtypes in circulation. Estimates presented in the study of yearly influenza-associated deaths with underlying pneumonia and influenza causes (1976–2007) reveal a large difference between influenza type A and B with a calculated median of greater than 6,000 deaths associated with influenza type A and half of that number for influenza type B (approximately 3,360) for persons 65 years of age and older. During the 22 seasons in which influenza A(H3N2) was the prominent strain, the average influenza-associated mortality rates were 2.7 times higher than for the nine seasons that it was not (all age groups combined), and on average, there were about 37% more annual influenza-associated deaths, regardless of the primary medical cause of death. A higher risk of hospitalization and death was also reported by Cromer et al. in adults 65 years of age and older, compared to younger adults in their assessment of the burden of influenza in England by age and clinical risk group\(^{(179)}\).

Canadian surveillance data show that hospitalization rates among adults 65 years of age and older were higher during the A(H3N2)-predominant 2014–2015 season compared to the previous five influenza seasons and also compared to the 2012–2013 season when A(H3N2) also predominated; 2014–2015 was a season in which there was a vaccine mismatch with the circulating A(H3N2) strain. Similar to the hospitalization rates, death rates among older adults were highest in the 2014–2015 season compared to the previous five seasons and compared to the previous A(H3N2) season in 2012–2013. Mortality rates among other age groups were similar to or lower than the previous five influenza seasons. Laboratory detections over this same time period showed that influenza seasons in which influenza subtype A(H3N2) predominated, disproportionally affected adults 65 years of age and older, while seasons with greater A(H1N1) detections resulted in a higher prevalence of positive cases in younger age groups.

**Adults 18–59 years of age**

Three types of influenza vaccine are authorized for use in adults 18–59 years of age: IIV3-SD, IIV4-SD, and LAIV4.

NACI recommends that any of the available influenza vaccines should be used in adults without contraindications. IIV should be used for pregnant women, adults with any of the chronic health conditions identified in List 1, and HCWs.

**Adults 60–64 years of age**

Two types of influenza vaccine are authorized for use in adults 60–64 years of age: IIV3-SD and IIV4-SD.

NACI recommends that any of the available age-appropriate influenza vaccines should be used.

**Adults 65 years of age and older**

Four types of influenza vaccine are authorized for use in adults 65 years of age and older: IIV3-SD, IIV3-Adj, IIV3-HD, and IIV4-SD.
Recommendation for individual-level decision making

When available, IIV3-HD should be used over IIV3-SD, given the burden of influenza A(H3N2) disease and the good evidence of better protection compared to IIV3-SD in adults 65 years of age and older. There is insufficient evidence to recommend the use of IIV3-HD over IIV4-SD. However, given the increased burden of disease associated with influenza A(H3N2) in older adults, better protection against influenza A(H3N2) may be more important than better protection against influenza B.

At this time, NACI does not make comparative recommendations on the use of IIV3-Adj or IIV4-SD over IIV3-SD or among IIV3-Adj, IIV3-HD, and IIV4-SD.

Any of the available influenza vaccines would be preferable to remaining unvaccinated or requesting individuals to return for vaccine. Therefore, in the absence of a specific product, NACI recommends that any of the available influenza vaccines should be used.

Recommendation for public health program-level decision making

IIV3-HD is expected to provide better protection compared to IIV3-SD; however, with cost-effectiveness assessments having been outside the scope of the evidence review, there is insufficient evidence to make a comparative recommendation on the use of these vaccines at the programmatic level. Therefore, NACI recommends that any of the available influenza vaccines should be used.

Refer to the NACI Literature Review Update on the Efficacy and Effectiveness of High-Dose (Fluzone® High-Dose) and MF59-Adjuvanted (Fluad®) Trivalent Inactivated Influenza Vaccines in Adults 65 Years of Age and Older for additional information supporting these recommendations.

Summary of vaccine characteristics for decision making

There are four types of inactivated influenza vaccines (IIV3-SD, IIV3-Adj, IIV3-HD, and IIV4-SD) authorized for use in Canada for adults 65 years of age and older. The comparison of vaccine characteristics across vaccine types, in Table 5 below, may be considered in making a decision on the preferred vaccine option(s) for use by an individual or a public health program. Due to a lack of available data directly comparing the performance of IIV3-Adj, IIV3-HD, and IIV4-SD, considerations for these vaccines in Table 5 are compared to IIV3-SD for which comparative data on efficacy, effectiveness, and/or immunogenicity with each of IIV3-Adj, IIV3-HD, and IIV4-SD are available.
### Table 5: Comparison of the vaccine characteristics of influenza vaccine types available for use in adults 65 years of age and older

<table>
<thead>
<tr>
<th>Considerations</th>
<th>Influenza vaccine type compared with IIV3-SD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IIV3-Adj</td>
</tr>
<tr>
<td>Burden of disease</td>
<td>Although influenza-associated morbidity and mortality varies each season, in general there is an increased burden of severe disease in adults 65 years of age and older during influenza seasons when influenza A(H3N2) predominates(^{(178)})</td>
</tr>
<tr>
<td>Efficacy and effectiveness</td>
<td>Insufficient evidence compared with IIV3-SD.</td>
</tr>
<tr>
<td>Immunogenicity</td>
<td>Non-inferior immune response compared to IIV3-SD. Superiority to IIV3-SD has not been consistently demonstrated.</td>
</tr>
<tr>
<td>Contraindications</td>
<td>Same contraindications as IIV3-SD.</td>
</tr>
<tr>
<td>Safety</td>
<td>Higher rate of injection site reactions than IIV3-SD. Higher or comparable systemic reactions compared to IIV3-SD; systemic reactions were mild to moderate and transient. SAEs were comparable to IIV3-SD and were uncommon.</td>
</tr>
</tbody>
</table>

**Abbreviations:** IIV3-Adj: adjuvanted trivalent inactivated influenza vaccine; IIV3-HD: high-dose trivalent inactivated influenza vaccine; IIV3-SD: standard-dose trivalent inactivated influenza vaccine; IIV4-SD: standard-dose quadrivalent inactivated influenza vaccine; SAE: serious adverse event.

\(^{a}\) NACI has not assessed the comparative cost-effectiveness of available influenza vaccine types for adults 65 years of age and older.
Adults with chronic health conditions

NACI recommends that any age-appropriate IIV, but not LAIV, should be offered to adults with chronic health conditions identified in List 1, including those with immune compromising conditions.

Pregnant women

NACI recommends that any age-appropriate IIV, but not LAIV, should be offered to pregnant women.

Due to a lack of safety data at this time, LAIV should not be administered to pregnant women due to the theoretical risk to the fetus from administering a live virus vaccine. LAIV can be administered to breastfeeding women.

Health care workers

NACI recommends that any age-appropriate IIV, but not LAIV, should be offered to HCWs.

Comparative studies in healthy adults have found IIV to be similarly or more efficacious or effective compared with LAIV\(^{(157)}\). In addition, as a precautionary measure, LAIV recipients should avoid close association with people with severe immune compromising conditions (e.g., bone marrow transplant recipients requiring isolation) for at least 2 weeks following vaccination, because of the theoretical risk for transmitting a vaccine virus and causing infection.
# LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AEFI</td>
<td>Adverse event following immunization</td>
</tr>
<tr>
<td>CAEFISS</td>
<td>Canadian Adverse Events Following Immunization Surveillance System</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CIG</td>
<td>Canadian Immunization Guide</td>
</tr>
<tr>
<td>DIN</td>
<td>Drug Identification Number</td>
</tr>
<tr>
<td>FFU</td>
<td>Fluorescent focus units</td>
</tr>
<tr>
<td>GBS</td>
<td>Guillain-Barré syndrome</td>
</tr>
<tr>
<td>GMT</td>
<td>Geometric mean titre</td>
</tr>
<tr>
<td>GMTR</td>
<td>Geometric mean titre ratio</td>
</tr>
<tr>
<td>HA</td>
<td>Hemagglutinin</td>
</tr>
<tr>
<td>HAART</td>
<td>Highly active antiretroviral therapy</td>
</tr>
<tr>
<td>HCW</td>
<td>Health care worker</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>Ig</td>
<td>Immunoglobulin</td>
</tr>
<tr>
<td>IIV</td>
<td>Inactivated influenza vaccine</td>
</tr>
<tr>
<td>IIV3</td>
<td>Trivalent inactivated influenza vaccine</td>
</tr>
<tr>
<td>IIV3-Adj</td>
<td>Adjuvanted trivalent inactivated influenza vaccine</td>
</tr>
<tr>
<td>IIV3-HD</td>
<td>High-dose trivalent inactivated influenza vaccine</td>
</tr>
<tr>
<td>IIV3-SD</td>
<td>Standard-dose trivalent inactivated influenza vaccine</td>
</tr>
<tr>
<td>IIV4</td>
<td>Quadrivalent inactivated influenza vaccine</td>
</tr>
<tr>
<td>IIV4-SD</td>
<td>Standard-dose quadrivalent inactivated influenza vaccine</td>
</tr>
<tr>
<td>ILI</td>
<td>Influenza-like illness</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IMPACT</td>
<td>Immunization Monitoring Program Active</td>
</tr>
<tr>
<td>LAIV</td>
<td>Live attenuated influenza vaccine</td>
</tr>
<tr>
<td>LAIV3</td>
<td>Trivalent live attenuated influenza vaccine</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>LAIV4</td>
<td>Quadrivalent live attenuated influenza vaccine</td>
</tr>
<tr>
<td>MMR</td>
<td>Measles, mumps and rubella</td>
</tr>
<tr>
<td>NA</td>
<td>Neuraminidase</td>
</tr>
<tr>
<td>NACI</td>
<td>National Advisory Committee on Immunization</td>
</tr>
<tr>
<td>ORS</td>
<td>Oculorespiratory syndrome</td>
</tr>
<tr>
<td>PHAC</td>
<td>Public Health Agency of Canada</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized controlled trial</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>RZV</td>
<td>Recombinant zoster vaccine</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>VE</td>
<td>Vaccine effectiveness</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
ACKNOWLEDGMENTS

This statement was prepared by: K Young, A Sinilaite, L Zhao, and I Gemmill, on behalf of the NACI Influenza Working Group and was approved by NACI.

NACI gratefully acknowledges the contribution of: O Baclic, A House, S Ismail, M Laplante, and M Tunis.

NACI Influenza Working Group

Members: I Gemmill (Chair), L Cochrane, N Dayneka, R Harrison, K Klein, D Kumar, J Langley, J McElhaney, A McGeer, D Moore, S Smith, and B Warshawsky.

Former member: M Lavoie.

Liaison representatives: L Grohskopf (Centers for Disease Control and Prevention [CDC], United States).

Ex-officio representatives: C Bancej (Centre for Immunization and Respiratory Infectious Diseases [CIRID], PHAC), P Wolfe-Roberge (First Nations and Inuit Health Branch [FNIHB], Indigenous Services Canada [ISC]), and J Xiong (Biologics and Genetic Therapies Directorate [BGTD], Health Canada [HC]).

Former ex-officio representative: K Watkins (CIRID, PHAC).

NACI

Members: C Quach (Chair), S Deeks (Vice-Chair), N Dayneka, P De Wals, V Dubey, R Harrison, K Hildebrand, C Rotstein, B Sander, N Sicard, and S Smith.

Former NACI members: M Lavoie and M Salvadori.

Liaison representatives: LM Bucci (Canadian Public Health Association), E Castillo (Society of Obstetricians and Gynaecologists of Canada), A Cohn (CDC, United States), M Naus (Canadian Immunization Committee), J Emili (College of Family Physicians of Canada), D Moore (Canadian Paediatric Society), M Naus (Canadian Immunization Committee) and A Pham-Huy (Association of Medical Microbiology and Infectious Disease Canada).

Former liaison representatives: J Brophy (Canadian Association for Immunization Research and Evaluation) and K Klein (Council of Chief Medical Officers of Health).

Ex-Officio representatives: J Gallivan (Marketed Health Products Directorate, HC), E Henry (CIRID, PHAC), M Lacroix (Public Health Ethics Consultative Group, PHAC), J Pennock (CIRID, PHAC), R Pless (BGTD, HC), G Poliquin (National Microbiology Laboratory, PHAC), and T Wong (FNIHB, ISC).

Former ex-officio representatives: K Barnes (National Defence and the Canadian Armed Forces).
REFERENCES


74. Gray GC, Trampel DW, Roth JA. Pandemic influenza planning: shouldn't swine and poultry workers be included? Vaccine. 2007;25(22):4376-81.


## APPENDIX A: CHARACTERISTICS OF INFLUENZA VACCINES AVAILABLE FOR USE IN CANADA, 2020–2021

<table>
<thead>
<tr>
<th>Product name (manufacturer)</th>
<th>Vaccine type</th>
<th>Route of administration</th>
<th>Authorized ages for use</th>
<th>Antigen content for each vaccine strain</th>
<th>Adjuvant</th>
<th>Formats available</th>
<th>Post-puncture shelf life for multi-dose vials</th>
<th>Thimerosal</th>
<th>Antibiotics (traces)</th>
<th>Production medium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quadrivalent</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flulaval® Tetra (GSK)</td>
<td>IIV4-SD (split virus)</td>
<td>IM</td>
<td>6 months and older</td>
<td>15 µg HA /0.5 mL dose</td>
<td>None</td>
<td>5 mL multi-dose vial</td>
<td>28 days</td>
<td>Yes</td>
<td>None</td>
<td>Egg (Avian)</td>
</tr>
<tr>
<td>Fluzone® Quadrivalent (Sanofi Pasteur)</td>
<td>IIV4-SD (split virus)</td>
<td>IM</td>
<td>6 months and older</td>
<td>15 µg HA /0.5 mL dose</td>
<td>None</td>
<td>5 mL multi-dose vial</td>
<td>Up to expiry date indicated on vial label</td>
<td>Yes</td>
<td>None</td>
<td>Egg (Avian)</td>
</tr>
<tr>
<td>Afluria® Tetra (Seqirus)</td>
<td>IIV4-SD (split virus)</td>
<td>IM</td>
<td>5 years and older</td>
<td>15 µg HA /0.5 mL dose</td>
<td>None</td>
<td>5 mL multi-dose vial</td>
<td>Up to expiry date indicated on vial label</td>
<td>Yes</td>
<td>Neomycin and polymyxin B</td>
<td>Egg (Avian)</td>
</tr>
<tr>
<td>Influvac® Tetra (BGP Pharma ULC, operating as Mylan)</td>
<td>IIV4-SD (subunit)</td>
<td>IM or deep subcutaneous injection</td>
<td>3 years and older</td>
<td>15 µg HA /0.5 mL dose</td>
<td>None</td>
<td>Single dose pre-filled syringe with or without a needle</td>
<td>Not applicable</td>
<td>No</td>
<td>Gentamicin or neomycin and polymyxin B</td>
<td>Egg (Avian)</td>
</tr>
<tr>
<td>FluMist® Quadrivalent (AstraZeneca)</td>
<td>LAIV4 (live attenuated)</td>
<td>Intranasal</td>
<td>2–59 years</td>
<td>(10^{6.5-7.5}) FFU of live attenuated reassortants /0.2 mL dose (given as 0.1 mL in each nostril)</td>
<td>None</td>
<td>Single use pre-filled glass sprayer</td>
<td>Not applicable</td>
<td>No</td>
<td>Gentamicin</td>
<td>Egg (Avian)</td>
</tr>
<tr>
<td>Product name (manufacturer)</td>
<td>Vaccine type</td>
<td>Route of administration</td>
<td>Authorized ages for use</td>
<td>Antigen content for each vaccine strain</td>
<td>Adjuvant</td>
<td>Formats available</td>
<td>Post-puncture shelf life for multi-dose vials</td>
<td>Thimerosal</td>
<td>Antibiotics (traces)</td>
<td>Production medium</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>----------------------------------------</td>
<td>----------</td>
<td>------------------</td>
<td>------------------------------------------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------------</td>
</tr>
<tr>
<td><strong>Trivalent</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agriflu® (Seqirus)</td>
<td>IIV3-SD (subunit)</td>
<td>IM</td>
<td>6 months and older</td>
<td>15 µg HA /0.5 mL dose</td>
<td>None</td>
<td>5 mL multi-dose vial</td>
<td>28 days</td>
<td>Yes (multi-dose vial only)</td>
<td>Kanamycin and neomycin</td>
<td>Egg (Avian)</td>
</tr>
<tr>
<td>Fluviral® (GSK)</td>
<td>IIV3-SD (split virus)</td>
<td>IM</td>
<td>6 months and older</td>
<td>15 µg HA /0.5 mL dose</td>
<td>None</td>
<td>5 mL multi-dose vial</td>
<td>28 days</td>
<td>Yes</td>
<td>None</td>
<td>Egg (Avian)</td>
</tr>
<tr>
<td>Fluzone® High-Dose (Sanofi Pasteur)</td>
<td>IIV3-HD (split virus)</td>
<td>IM</td>
<td>65 years and older</td>
<td>60 µg HA /0.5 mL dose</td>
<td>None</td>
<td>Single dose pre-filled syringe</td>
<td>Not applicable</td>
<td>No</td>
<td>None</td>
<td>Egg (Avian)</td>
</tr>
<tr>
<td>Fluar Pediatric® and Fluad® (Seqirus)</td>
<td>IIV3-Adj (subunit)</td>
<td>IM</td>
<td>Pediatric: 6–23 months; Adult: 65 years and older</td>
<td>Pediatric: 7.5 µg HA /0.25 mL dose; Adult: 15 µg HA /0.5 mL dose</td>
<td>MF59</td>
<td>Single dose pre-filled syringe without a needle</td>
<td>Not applicable</td>
<td>No</td>
<td>Kanamycin and neomycin</td>
<td>Egg (Avian)</td>
</tr>
</tbody>
</table>

**Abbreviations:** FFU: fluorescent focus units; HA: hemagglutinin; IIV3-Adj: adjuvanted trivalent inactivated influenza vaccine; IIV3-HD: high-dose trivalent inactivated influenza vaccine; IIV3-SD: standard-dose trivalent inactivated influenza vaccine; IIV4-SD: standard-dose quadrivalent inactivated influenza vaccine; IM: intramuscular; LAIV4: quadrivalent live attenuated influenza vaccine; NA: neuraminidase.

*a Full details of the composition of each vaccine authorized for use in Canada, including other non-medicinal ingredients, and a brief description of its manufacturing process can be found in the product monograph.

*b Neomycin and polymyxin B are only used if gentamicin cannot be used. No trace amounts of neomycin or polymyxin B are present if gentamicin was used.